Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 18, 2026.

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

Gurcan Gunaydin, M. Emre Gedik, Seylan Ayan

Frontiers in Chemistry · 2021 · Review · CC BY

doi:10.3389/fchem.2021.686303

Abstract

Photodynamic therapy (PDT) has been used as an anti-tumor treatment method for a long time and photosensitizers (PS) can be used in various types of tumors. Originally, light is an effective tool that has been used in the treatment of diseases for ages. The effects of combination of specific dyes with light illumination was demonstrated at the beginning of 20th century and novel PDT approaches have been developed ever since. Main strategies of current studies are to reduce off-target effects and improve pharmacokinetic properties. Given the high interest and vast literature about the topic, approval of PDT as the first drug/device combination by the FDA should come as no surprise. PDT consists of two stages of treatment, combining light energy with a PS in order to destruct tumor cells after activation by light. In general, PDT has fewer side effects and toxicity than chemotherapy and/or radiotherapy. In addition to the purpose of treatment, several types of PSs can be used for diagnostic purposes for tumors. Such approaches are called photodynamic diagnosis (PDD). In this Review, we provide a general overview of the clinical applications of PDT in cancer, including the diagnostic and therapeutic approaches. Assessment of PDT therapeutic efficacy in the clinic will be discussed, since identifying predictors to determine the response to treatment is crucial. In addition, examples of PDT in various types of tumors will be discussed. Furthermore, combination of PDT with other therapy modalities such as chemotherapy, radiotherapy, surgery and immunotherapy will be emphasized, since such approaches seem to be promising in terms of enhancing effectiveness against tumor. The combination of PDT with other treatments may yield better results than by single treatments. Moreover, the utilization of lower doses in a combination therapy setting may cause less side effects and better results than single therapy. A better understanding of the effectiveness of PDT in a combination setting in the clinic as well as the optimization of such complex multimodal treatments may expand the clinical applications of PDT.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Light is an effective tool that has been used in the treatment of maladies for ages. It was utilized in the treatment of skin diseases in ancient Egypt, India, and China. In addition, photochemotherapy has been used as a treatment method for a long time. It is known that psoralens were used in India around 1400 BC. In Atharva Veda, which is a collection of Vedic Sanskrit incantations, spells, and hymns, it is stated that Hindus used the psoralens obtained from the seeds of Psoralea corylifolia for the repigmentation of the vithlogenic skin, utilizing the ancient Ayurvedic medicine. In Ancient Egypt, the Sun represented an important part of the culture and sunlight could be associated with healing properties. The importance of the Sun in Ancient Egypt resulted in its utilization in terms of heliotherapy (Figure 1A). Figure 1 demonstrates phototherapy in Ancient Egypt. The Ebers papyrus (a total length of 20 m) represents the largest record of Ancient Egyptian medicine and the Papyrus (circa 1500 BC) mentions about vitiligo (Figure 1B). It is known that Egyptians extracted psoralen from the Ammi majus (bishop’s weed) plant growing on the south bank of the Nile and used it in the treatment of leukoderma in the 12th century AD. Heliotherapy (the use of sunlight or of another source of UV, visible or infrared radiation for therapeutic purposes), which was systematically recorded and described to be used for medicinal purposes by Herodotus in ancient Greece, was applied as an effective treatment method for various diseases. In the 18th and 19th centuries, sunlight therapy was used to treat various ailments such as tuberculosis, rickets, scurvy, rheumatism, paralysis, edema, and muscle weakness. However, its utilization in modern medicine started in the 20th century. At the beginning of the 20th century, Danish physician Niels Ryberg Finsen reported that he treated chickenpox under red light by preventing inflammation of the pustules. In the following years, he was awarded with the 1903 Nobel Prize in Physiology or Medicine for “his contribution to the treatment of diseases, especially lupus vulgaris, with concentrated light radiation”.

History of Photodynamic Therapy

The idea of using photodynamic therapy (PDT) as a new treatment strategy was suggested in the early 1900s. In fact, the extraction of hematoporphyrin from dried blood by Schere via removing iron in 1841 is an important milestone for the field of photosensitizers (PSs). A researcher named Oscar Raab observed that paramecia died when incubated under the light with acridine red dyes in Germany. He also observed that those that were not exposed to light remained alive. In fact, initial observations related with PDT in medicine refer to the inactivation of microorganisms more than a hundred years ago. Thus, the definition of photodynamic action emerged based on this observation. Indeed, Hermann von Tappeiner coined the term “photodynamic reaction”, underlining the fact that light played an important role (v.; ). PDT of infections, which involves reactive oxygen species (ROS) to disrupt and kill microbes, can be useful against bacteria and viruses. Due to the World Wars, the evolution of the idea has been delayed for nearly 60 years.

In 1960, generation of new approaches in terms of PDT started with the studies by R. L. Lipson and S. Schwartz at the Mayo Clinic. Lipson et al. reported that malignant diseases could be detected by using an acetic acid-sulfuric acid derivative of hematoporphyrin and proper filter systems for activating and viewing the fluorescence. Schwartz treated hematoporphyrin with acetic acid and sulfuric acid and obtained a porphyrin mixture in order to achieve optimal tumor localization. He termed this mixture as hematoporphyrin derivative (HpD), which contains several porphyrins, monomers as well as dimers and oligomers. Lipson et al. used HpD in order to detect tumors. In 1967, Lipson et al. reported the use of hematoporphyrin derivative in patients for lesions of the esophagus and tracheobronchial tree, cervix and vagina, rectum, breast, tonsil, parotid and intraperitoneal lesions. They proposed that this approach could be helpful in terms of detection and subsequent management of malignant diseases. The utilization of HpD in bladder cancer treatment was reported by Kelly and Snell as one of the first clinical applications in 1976. In the following years, HpD was transformed into a drug formulation by Dougherty. Dougherty et al. reported the first clinical case of PDT in a patient with metastatic breast cancer to the skin in 1978. Furuse et al. conducted phase II clinical trials using Photofrin (porfimer sodium) for early-stage lung cancer between June 1989 and February 1992. In 1993, PDT with Photofrin obtained the first health agency approval in Canada for the treatment of bladder cancer. The Food and Drug Administration (FDA) approved Photofrin for esophageal cancer in 1995. In addition, Photofrin was approved for the treatment of early non-small cell lung cancer in 1998.

Indeed, PSs have been used as therapeutic agents for more than a century. The timeline of PDT can be seen in Figure 2. The clinical use of eosin in the treatment of skin cancer may be given as one example of the first PDT applications. Tappeiner and Jesionek aimed to treat skin tumors by using topical eosin. PSs are classified into three generations based on their evolution. Table 1 demonstrates examples of first, second and third generation PSs.

Naturally occurring porphyrins and their derivatives constitute the first generation of PSs. Figure 3 demonstrates examples of first and second generation PSs. Hematoporphyrin, which was used in cancer treatment in the 1950s, and Photofrin, which was approved by the FDA in the treatment of various cancers such as lung, esophagus, and cervix, are among the examples of first generation PSs. Indeed, most first generation PSs were developed around 1970s. The first generation PSs were used in early clinical trials of PDT. Even though first generation PSs were thought to demonstrate favorable photodynamic activity, they bear important disadvantages such as dark cytotoxicity, cutaneous phototoxicity and low absorption bands at red wavelengths as well as issues related with hydrophobicity.

Second generation PSs were developed in order to overcome the problems associated with first generation PSs (Figure 3). Second generation PSs include 5-aminolevulinic acid, benzoporphyrin, chlorin and phthalocyanine. In general, second generation PSs are activated with wavelengths above 650 nm and they demonstrate less phototoxicity. In addition, the clearance of second generation PSs from normal tissues is quicker than that of porphyrins. Second generation PSs also demonstrate high singlet oxygen quantum yield and high solubility in water. Although they can be used in various types of cancer, they might still cause tissue damage due to high toxicity as well as demonstrating low stability. In order to achieve more accurate targeting, various chemical modifications can be made. Such approaches resulted in the generation next generation PSs. Indeed development of specific carriers for the delivery of PSs aiming to cause less phototoxicity in normal tissues may help to improve PDT outcomes.

Third generation PSs utilize available drugs by modifying them. Third generation PSs usually consist of second generation PSs that were modified with specific agents (e.g., antibody conjugation) or were encapsulated into carriers in order to increase the accumulation at the target area. Indeed, current studies aim to develop third generation PSs in order to decrease off-target effects and to improve pharmacokinetic properties. An important concept in terms of third generation PSs is the utilization of molecular carriers such as nanoparticles. Such carriers are mainly utilized in order to deliver various PSs to the cells, given the probable poor water-solubility of the PSs. Various carrier molecules are developed in order to increase the effectiveness of PDT such as liposome, micelle, quantum dot, dendrimer, polymer; magnetic gold, and carbon-based nanoparticles. For instance, chlorin E6 was incorporated into nanoparticles via formation of ion complexes in order to increase absorption by the tumor.

Encapsulation of drugs into delivery systems has been as area of extensive research over the last years. Although bioconjugation and encapsulation with targeting moieties seem to be critical approaches in order to develop more effective and specific PSs, it should also be borne in mind that an ideal PS should achieve high quantum yield, display long-wave absorption, cause low dark toxicity, demonstrate favorable pharmacokinetic properties, have high purity and stability. Furthermore, becoming activated at different wavelengths and having amphiphilic properties can also be considered among the favorable features for PSs. Last but not least, it should be kept in mind that classifying drugs into generations does not necessarily mean that all newer drugs are better that the older ones. Future clinical studies comparing the effectiveness as well as adverse effects of different PSs in large cohorts of patients will pave the way for the development of more potent PSs.

Clinical Applications of Photodynamic Therapy in Cancer

PDT is an approach which mainly requires three components, i.e. a photosensitizer, light and oxygen. Mechanisms of action of PDT on tumors can be seen in Figure 4. In general, PSs are in inactive state unless they are exposed to specific light. Moreover, photodynamic activity is dependent on the presence of oxygen. The light activated PS generates ROS, which mainly result in the effector functions (e.g., killing of tumor cells). PDT comprises two stages of clinical treatment, combining light energy with a PS in order to destroy tumor cells after activation by light (Figure 5 demonstrates therapeutic application of PDT). Several side effects and limitations can restrict the use of some PDT agents. Problems such as lack of selectivity, poor water-solubility, possible toxic effects on healthy tissues, skin photosensitivity that is associated with certain PSs may prevent the clinical applications of various PDT approaches. Many research groups have undertaken the task to overcome such issues and several promising targeted approaches have been reported over the last years. Novel innovative strategies aim to increase the delivery of PSs to tumor tissues, to augment specificity and to increase efficiency. Further clinical studies and proof of principle approaches will pave the way for better PDT modalities.

Clinical Efficacy of Photodynamic Therapy in Cancer

PDT was the first drug/device combination approved by the FDA. Various PSs have been commercialized or used in clinical trials up to date. One of the most frequently used PSs in the clinic is Photofrin (porfimer sodium). The first approval of PDT with Photofrin was obtained in Canada in 1993 for the treatment of bladder cancer. In Netherlands and France, Photofrin was approved for the treatment of advanced lung cancers, whereas it was approved in Germany for the treatment of early stage lung cancer. In summary, Photofrin has been approved by the FDA for three indications, i.e. palliation of patients with esophageal cancer; treatment of microinvasive endobronchial non-small-cell lung cancer (NSCLC) and reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC; and ablation of high-grade dysplasia in Barrett’s esophagus. Selected PSs approved by the FDA can be seen in Table 2. It is activated by red light from a laser. Aminolevulinic acid (ALA) has been approved by the FDA for the indication of topical treatment of minimally to moderately thick actinic keratoses of the face or scalp, or actinic keratoses of the upper extremities (in summary) (Table 2). In addition, oral solution of ALA has been approved by the FDA as an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery (in summary) (Table 2). Methyl aminolevulinate has been approved by the FDA for the indication of treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratoses of the face and scalp in immunocompetent patients (in summary) (Table 2). Hexaminolevulinate has been approved by the FDA as an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder (in summary) (Table 2). Indeed, several preclinical and clinical studies are ongoing in order to develop new PSs and PDT approaches.

Therapeutic Applications of Photodynamic Therapy

Photodynamic therapy is indeed a treatment method used to treat various diseases utilizing the photosensitizer’s photophysical and chemical properties. Mechanistically, photodynamic treatment consists of two steps. The first step is the excitation of PS, which is induced by light. Two groups of light sources can be utilized in terms of the photoexcitation stage of PDT, i.e., laser and non-laser. Light sources utilized in PDT can be seen in Figure 6. Laser light sources include Argon Lasers and Argon-pumped Dye Lasers, Metal Vapor-pumped Dye Lasers, Solid State Lasers, Optical Parametric Oscillators, and Diode Lasers. On the other hand, Tungsten Filament Quartz Halogen Lamps, Xenon Arc Lamps, Metal Halide Lamps, Phosphor-coated Sodium Lamps, and Fluorescent Lamps are among the non-laser light sources. In addition to these sources, Light Emitting Diodes (LED) and Femtosecond Solid State Lasers may also be utilized.

The reaction of the photochemically excited PS with molecular oxygen constitutes the second step of PDT. Upon excitation by specific light, one of the electrons of the PS in the ground state (S0), which has two electrons in opposite spins in a molecular orbit involving lower energy, is excited towards the molecular orbit involving higher energy (singlet state = S1) without changing its spin. According to the Jablonski energy diagram, PS with high energy orbit or singlet state can transform to the ground state in a short time by fluorescent radiation (emission) or heat releasing (internal conversion = IC) (Figure 4). By performing intersystem crossing (ISC) to the triplet state, it may transform into a long-lasting form. The triplet state’s transformation occurs in parallel with the transformation in the singlet state by phosphorescence radiation (emission) or heat releasing (IC). When PDT is applied in biological systems, PS reaches a high-energy triplet state as a result of the absorption of light. Then, PS reacts with cellular substrates (biomolecules) (Type I reaction) and ROS are generated. On the other hand, energy transfer to molecular oxygen (excitation energy transfer, EET) leads to the conversion of oxygen to singlet oxygen (Type II reaction) (Figure 4). In both cases, the reaction of the generated molecules with vital cellular components such as lipids, proteins, and nucleic acids can result in toxicity to the organism.

Depending on the type of PDT and its ROS production efficiency, PDT may affect cellular antioxidants and heat shock proteins as well as anti-tumor immune responses. Transformation of ROS into nontoxic molecules is catalyzed by antioxidant enzymes inside the cell, such as superoxide dismutase, catalase and glutathione peroxidase. Antioxidant enzymes take active part in the breakdown of superoxide anions and hydrogen peroxides that accumulate in the cell. Additionally, small molecules such as glutathione, vitamins E and C also help to ensure intracellular control of ROS. It has been reported that cancer cells generate more ROS than normal cells. Therefore, cancer cells require a robust antioxidant system in order to be able to survive. It was reported that the cytotoxic effects of PDT are enhanced when antioxidant enzymes or glutathione synthesis mechanisms are targeted during PDT. It was demonstrated that l-buthionine sulfoximine, which is a glutathione synthesis inhibitor, boosts PDT effects. Similarly, targeting cyclooxygenase, which regulates inflammation and homeostasis, and heat shock proteins, which are activated by oxidative stress and have an essential functional role in protein folding, can increase the effectiveness of PDT. PDT might achieve direct killing of tumor cells by generating ROS or singlet oxygen in the tumor cells. Moreover, it can also result in tumor associated vascular damage and; hence, tumor infarction. Finally yet importantly, PDT may also induce enhanced immune responses against the tumor.

PDT generally demonstrates fewer side effects and less toxicity than chemotherapy and/or radiotherapy used in conventional cancer treatment. Indeed, PDT has been used in cancer treatment for some time. More than two hundred clinical trials have been conducted until recently. In addition, there are currently numerous ongoing studies. Selected studies can be seen in Table 3. In a porfimer sodium based PDT study conducted with 1,440 patients diagnosed with basal cell carcinoma, which is the most common skin cancer type, PDT was reported to demonstrate an initial complete response rate of 92%, with a recurrence rate of less than 10% at 4 years. In addition to cancer, PDT may also be used in other diseases such as those of the skin and the eye. It is also an effective treatment option for Barrett’s esophagus, unresectable cholangiocarcinoma and non-melanoma skin lesions.

Targeting Strategies in Photodynamic Therapy

Tumor-targeted PDT can be divided into two groups, i.e., passive targeting and active targeting. Passive targeting takes advantage of physiological and morphological differences between normal and tumor tissues to achieve tumor-selective targeting as well as PS accumulation. The uncontrolled proliferation of tumor cells results in vessels with irregular structure. Tumor vessels are usually leaky and tortuous with irregular branching in contrast to normal tissues. Due to the heterogeneous structure of the vessels as well as the basement membrane and irregular endothelial cells, most drugs that are administered accumulate in tumor tissues. In addition, components of the extracellular matrix (ECM) such as collagen, elastin and hyaluronan are generally expressed more in tumor tissues than their normal counterparts. Although such conditions can be regarded as an obstacle for the transfer of some drugs, it is known that porphyrin derivatives interact with collagen. Semi-specific passive targeting may be achieved via using such characteristics of the tumor.

Various surface receptors are expressed more by tumor cells than normal cells. Such receptors can be utilized in terms of active targeting. For instance, HER2 is overexpressed in 15–30% of invasive breast cancers. HER2, which is also known as ErbB2, is a member of the HER receptor family. Breast cancers may bear up to 25–50 copies of the HER2 gene, resulting in an estimated number of two million receptors expressed at the tumor cell surface, while a normal cell surface has much less HER2 receptors. Such a difference in receptor expression underlies an active targeting strategy, which takes advantage of the combination of PDT with trastuzumab. Indeed, trastuzumab, which is a humanized anti-HER2 antibody, is the first HER2-targeted therapeutic monoclonal antibody approved by the FDA in 1998 for the therapy of metastatic HER2+ breast cancer. In addition to targeting receptors with specific monoclonal antibodies, conjugation of PSs with specific ligands that bind to the receptors is also a promising approach. Mannose conjugated PSs to target mannose receptors that may be overexpressed in breast cancer cells, EGF conjugated PSs for targeting EGFR receptors, cannabinoid CB2 receptor (a G-protein coupled receptor)/translocator protein (a mitochondria membrane receptor) targeted PSs can also be utilized for active targeting strategies in breast cancer.

It is widely known that the tumor milieu contains various types of cells in addition to tumor cells (e.g., immune cells and fibroblasts). The efficacy of PDT may be affected by the components of the complex tumor microenvironment. Thus, recent approaches incorporating nanotechnology strategies in order to augment the effects of PDT via remodeling the tumor microenvironment (e.g., reshaping tumor vessels, ECM, and anti-tumor immune responses) are exciting. Moreover, increased selectivity for cancer cells may be achieved by altering PSs with bioresponsive elements. Targeting overexpressed enzymes in tumor cells in contrast to normal cells is an encouraging approach in order to generate ROS specifically in tumor cells.

In normal healthy cells, glucose taken into the cell under normoxic conditions is broken down into pyruvate in the cytosol. The pyruvate is transported to the mitochondria, where it is oxidized by pyruvate dehydrogenase. This is followed by the citric acid cycle. Under anoxic or hypoxic (low partial oxygen pressure) conditions, the reduction of pyruvate to lactate is catalyzed by lactate dehydrogenase. Pyruvate cannot be transported to the mitochondria, with the inhibition of pyruvate dehydrogenase by pyruvate dehydrogenase kinase (PDK). Indeed, hypoxia is a common feature of the tumor microenvironment. While approximately 38 ATP molecules are generated as a result of each cycle in healthy aerobic cells, 2 ATP molecules are generated as a result of each cycle in the cancer cells. Cancer cells maintain energy production by increasing the expression of glucose transporter (GLUT) on the cell surface and; thus, glucose uptake into the cell. It is known that cancer cells prefer aerobic glycolysis under normoxic (typical oxygenated environment) conditions. This mechanism is called the Warburg effect. Thus, novel PDT approaches can also be based on the Warburg effect. Kataoka et al. reported developing a third generation PDT by synthesizing a sugar conjugated chlorin PS, with enhanced cancer cell selective accumulation, since tumors cells consume higher levels of glucose than normal cells due to the Warburg effect. They reported that glucose conjugated chlorin based PDT demonstrated more potent anti-tumor effects than second generation talaporfin mediated PDT. Moreover, PDT with glucose conjugated chlorin was found to induce immunogenic cell death. In another study, Gan et al. reported that pyruvate kinase M2, which is a rate-limiting enzyme of glycolysis, was downregulated and glucose uptake was inhibited in cells that were exposed to PDT with 5-aminolevulinic acid (5-ALA) at 4 h after treatment. Interestingly, they reported important increases in PKM2 expression and glucose uptake at 24 h after PDT. Such findings suggest that PDT may indeed drive the Warburg effect in a time dependent manner.

5-ALA is a frequently used PDT agent, due to its high endogenous accumulation. It is the first compound in the porphyrin synthesis pathway that results in chlorophyll in plants and heme in mammals. 5-ALA, which is synthesized under physiological conditions from succinyl coenzyme A and glycine in mitochondria, leads to the biosynthesis of protoporphyrin IX (PpIX), the last precursor of heme in mitochondria. PpIX is then catalyzed by ferrochelatase, which produces hemoprotein (heme) by reducing the iron (III) ion to iron (II). At the end of this process, heme is produced. Due to the Warburg effect seen in cancer cells, the enzyme ferrochelatase becomes inactive. This leads to the increased accumulation of PpIX in cancer cells as a result of the utilization of exogenous 5-ALA. As a result of PDT via the photoactive feature of PpIX; ROS and singlet oxygen as well as superoxides increase in the cell, which in turn result in cellular death. In addition to PDT applications with 5-ALA and hexaminolevulinate, which is used as an optical imaging agent in the cystoscopic detection of carcinoma of the bladder, monoclonal antibody conjugated PDT and photoimmunotherapy (PIT) strategies are currently being developed.

Limitations of Photodynamic Therapy

PDT is generally ineffective for large or deep-seated tumors due to the limited penetration depth of light in biological tissues. One of the major limitations of PDT is that it cannot be applied to the whole body in advanced stage cancer. For this reason, its utilization is limited to the treatment of precancerous lesions and regional malignancies. Difficulty in treating large tumor masses is another issue in terms of clinical PDT. Moreover, singlet oxygen, which is generated as a result of PDT, has a very short half-life. Thus, the effects of PDT are mainly limited to the area of photosensitization. Given the fact that PDT is highly dependent on the presence of oxygen in the tissues, tumor hypoxia can significantly hamper the effectiveness of PDT. Indeed, depletion of oxygen due to PDT itself might also decrease PDT efficiency. In addition, problems related with skin toxicity should also be taken into account in terms of clinical PDT applications.

The period of time between the administration of the drug and the application of light is called the drug-light interval. Optimum drug-light intervals are mostly assumed to be the times at which there is a maximum differential in PS retention between the tumor and normal tissue. However, optimum drug-light interval might vary from patient to patient or lesion to lesion. Such variations render the application of standardized protocols difficult. It should also be borne in mind that tumor destruction via targeting the vascular structures is also an important part of clinical PDT. Thus, plasma levels of the PSs as well as the exposure of endothelial cells to the PSs may prove to be crucial factors for effective PDT. Indeed, Li and Luo demonstrated that the anti-tumor effects of Photofrin PDT were achieved mostly by the destruction of tumor blood vessels at short drug-light intervals. On the other hand, tumor cells were destroyed directly by PDT mediated cytotoxicity at long drug-light intervals. In general, PSs that directly destruct the target cells should have a relatively longer drug-light interval. On the other hand, PSs with a short drug-light interval may be targeted to tumor related vascular structures rather than the tumor cells in order to improve the effectiveness of treatment.

Moreover, the depth of PDT application in cancer treatment is limited, given the fact that light cannot penetrate beyond a few millimeters of tissue. The treatment efficiency decreases in deep-seated and spreading tumors due to the low tissue penetration of light. The deep-PDT strategy, which was developed with new photo converting nanoparticles and/or NIR light/X-ray/self-luminescence excitation methods, aims to overcome this limitation. One approach takes advantage of the two-photon excitation technique, which involves absorption of two photons in order to reach an excited state. This technique, which allows for the activation of PSs with two-photon absorption, may aid in improving light penetration depth.

Assessment of Photodynamic Therapy Therapeutic Efficacy in the Clinic

It is of utmost importance to identify early predictors in order to determine the response to treatment. Huang et al. reported that gadolinium contrast-enhanced magnetic resonance imaging (MRI) is superior to diffusion weighted images at 7 days after PDT. The MRI results correlated with the percentage of necrosis in a canine model. On the other hand, Haider et al. demonstrated that contrast-enhanced MRI showed irregular margins of intra-prostatic treatment effect and suggested that tissue sensitivities to vascular targeted PDT with palladium-bacteriopheophorbide varied. Sirotkina et al. utilized optical coherence angiography to monitor treatment response following vascular targeted PDT. In another study, Gross et al. investigated the utilization of blood oxygenation level-dependent contrast MRI in order to monitor real-time efficacy of PDT. Such an approach might be useful in monitoring PDT treatment. Bioluminescence imaging was also investigated as a means of success rate assessment 24 h after vascular targeted PDT. Luciferase transfected (luminescent) tumor cells allowed for the imaging of the tumor before and 24 h after PDT. PDT treatment response was assessed based on the presence of bioluminescence imaging signal. Using the treatment response information, researchers treated the mice that failed the first treatment again; thus, reaching a cumulative treatment success rate of 90% from 75%. The utilization of bioluminescence imaging in in vivo animal models may assist in determining response to PDT. Ultrasonography, which is cheaper than MRI, may also prove to be useful in terms of assessing PDT efficacy and it may improve PDT mediated outcomes in cancer. Ultrasonography can be implicated in tracking the uptake of PS, destruction of vessels and evaluating the overall tumor responses. The tissue distribution of the PS can also be evaluated by taking biopsy samples and analyzing the fluorescence. Furthermore, strategies to detect intratumoral drug, light and oxygen in order to monitor treatment have also been investigated. In addition to such strategies, computer modelling of PDT can also be helpful, as such approaches may assist PDT in the clinical setting.

Photodynamic Diagnosis

Several types of PSs can be used for diagnostic purposes in terms of tumors. Such approaches are generally called photodynamic diagnosis (PDD). As its name implies, PDD utilizes fluorescent PS agents in order to identify tumor tissues. In PDD, a PS which is selective for the target tumor cells is utilized. The PS can be excited with a light source at a specific wavelength. The emitted light enables identification of the tumor cells. PDD can be regarded as part of fluorescent guided resection, which is a kind of Image Guided Surgery. This approach has the potential to improve clinical outcome. PDD can turn into PDT via increasing the intensity/duration of photoirradiation. It should be noted that ROS that are generated in PDT are able to harm the PS, causing the PS to become non-fluorescent. ALA seems to have a potential for PDD in various tumors, due to its ability to discriminate neoplastic tissues from normal tissues. ALA fluorescence microscopy has been proposed to be a specific biological tumor marker for malignant glioma resection. It may assist in discriminating tumor tissue from normal brain tissue. Stummer et al. reported that ALA enabled more complete resections of contrast-enhancing tumor, resulting in improved progression free survival in patients with malignant glioma. Moreover, PDD was reported to detect more bladder tumor-positive patients, especially more with carcinoma in situ, than white-light cystoscopy. Kausch et al. concluded that a longer recurrence free survival was achieved and more patients had a complete resection when diagnosed with PDD. Similarly, Mowatt et al. reported that PDD identified more bladder tumors than white-light cystoscopy. PDD with ALA enabled a more complete approach at transurethral resection of bladder tumor and improved recurrence-free survival. Turan et al. demonstrated a concept of molecular demultiplexer, which is able to autonomously switch modes from PDT to PDD when apoptosis is induced. Such an intelligent molecular automaton has shown a way of moving ahead to meet the challenge of confinement of unintended damage by excessive 1O2 production. It is clear that early detection of a tumor is very important in terms of improving survival rate. Furthermore, combination of PDD and PDT may prove to be very efficient. Near infrared fluorescence imaging is most likely to improve the concept of tumor targeted imaging, due to the features such as low tissue auto-fluorescence and high tissue penetration depth of near infrared spectrum.

Photodynamic Therapy Combined With Other Therapy Modalities

Combination of PDT with other therapeutic modalities seems to be promising in terms of enhancing effectiveness against tumor. Several features of PDT such as minimal systemic effects and low long term morbidity render it a suitable option for combination therapy approaches. PDT has been proposed to be effectively combined with other anti-cancer therapeutic modalities, as the mechanism of action of PDT is unique. Given the fact that the targets of radiotherapy, chemotherapy and PDT differ; combination of PDT with such treatments may yield better results than by single treatments. Moreover, the utilization of lower doses in a combination therapy setting may cause less side effects and better results than single therapy. In a study by Gupta et al., PDT with the use of intratumoral administration of specific antibodies conjugated to PSs was proposed to significantly reduce the toxicity to normal tissues. Conjugating PSs with monoclonal antibodies that are specific for antigens on tumor cells may allow for the targeting of tumors. Bai et al. proposed that gene therapy and PDT could be combined for treating nasopharyngeal carcinoma.

PDT Combined With Chemotherapy

Nahabedian et al. demonstrated that combination of PDT with chemotherapy can yield increased tumoricidal effects. Several types of tumors were reported to display resistance to platinum analogues and platinum nanomaterials were suggested as possible alternatives for anti-tumor treatment. Wang et al. reported that combined chemotherapy and PDT was effective in terms of killing cisplatin resistant tumor cells. Similarly, Antoni et al. also reported an additive effect of cisplatin and a zinc porphyrin on human ovarian cancer cells. Moreover, PDT might be implicated in attenuating drug resistance. Multidrug resistance (MDR) is a critical mechanism, which can cause tumor cells to become resistant to chemotherapeutic drugs. The development of MDR to chemotherapy may constitute an important issue in terms of the treatment of tumors. Several mechanisms have been found to be associated with resistance to chemotherapy such as cellular pumps dependent, increased metabolism of drugs, decreased drug entry and defective apoptotic pathways. Hence, targeting MDR via chemosensitizers combined with anti-tumor compounds is an interesting approach. In line with such studies, PDT is able to attenuate multidrug resistance via decreasing drug efflux by lowering P-glycoprotein level. Thus, combination of PDT and chemotherapy may be useful in terms of preventing drug resistance. Jin et al. reported that combination of PDT and chemotherapy may prove to be effective against cardiac cancer. In another study, the combined chemotherapy and PDT with N-(2-hydroxypropyl) methacrylamide copolymer-bound anti-cancer drugs was shown to be effective against human ovarian carcinoma in nude mice. Ma et al. studied the combination of PDT with meso-tetra (di-adjacent-sulphonatophenyl) porphine and vincristine or taxol in a mouse mammary tumor model. They found an increased anti-tumor effect when vincristine was administered 6 h before PDT. In addition, they also reported that the anti-tumor activity of PDT could be enhanced when taxol was utilized 6 h prior to PDT or immediately after or before PDT. Khdair et al. analyzed the anti-cancer efficacy of doxorubicin in combination with methylene blue mediated PDT in a mouse mammary adenocarcinoma tumor model. The results showed that nanoparticle mediated combination chemotherapy and PDT using doxorubicin and methylene blue had a therapeutic potential. Canti et al. investigated the effects of PDT with photoactivated aluminum disulfonated phthalocyanine combined with Adriamycin (doxorubicin) and cisplatinum on murine tumors. Mice with leukemia and lymphoma were treated with Adriamycin or cisplatinum and then with PDT. Combination of antiblastic drugs with PDT showed an additive anti-tumor effect. Therefore, such a combination was suggested to have the potential to decrease the effective doses of antiblastic drugs, as well as reducing toxic effects on normal tissues. Kästle et al. analyzed the effects of combination of PDT with heme oxygenase I and poly (ADP-ribose) polymerase inhibitors on melanoma cells in comparison to nonmalignant keratinocytes. The researchers concluded that heme oxygenase I and poly (ADP-ribose) polymerase inhibitors could augment the efficiency of PDT.

In addition, combination of PDT with anti-angiogenic drugs may also prove to be useful. For this purpose, anti-angiogenic monoclonal antibodies may be utilized. Hypoxia is an important feature of several solid tumors and can cause induction of angiogenesis. Zhou et al. reported that efficiency of PDT could be increased by anti-angiogenic therapy. Ferrario et al. demonstrated that combination of anti-angiogenic treatment and PDT enhanced tumoricidal effects in comparison to individual treatments in mice. In another study, Ferrario et al. showed that bevacizumab (a monoclonal antibody against vascular endothelial growth factor A [VEGF-A]) could augment the efficiency of PDT. They suggested that inhibitors of VEGF have a potential to improve the clinical efficacy of PDT. Similarly, Bhuvaneswari et al. reported that combination of hypericin mediated PDT and bevacizumab improved tumor response. In addition, another study showed that combination of PDT with anti-angiogenic treatment resulted in inhibition of tumor growth and improved survival in mice in comparison to individual treatments. Thus, such a combination approach can be promising in terms of improving clinical results in glioblastoma.

PDT Combined With Radiotherapy

Allman et al. reported that combination of 5-aminolaevulinic acid mediated PDT and gamma-irradiation caused a level of cytotoxicity which is additive and not synergistic. Another study by Luksiene et al. showed that hematoporphyrin dimethyl ether mediated PDT and radiotherapy resulted in the inhibition of tumor growth. Furthermore, combining PDT and radiotherapy yielded an additive effect. Nakano et al. reported that the treatment rate of Bowen’s disease might be enhanced via combination therapy with 5-aminolevulinic acid mediated PDT and radiation therapy. The combinations of two of the modalities of Photofrin II-sensitized photochemotherapy, an electric current and ionizing radiation were reported to act mainly additively or synergistically.

Photodynamic Therapy Combined With Surgery

Combinations of PDT with surgery have been studied by several groups. Rigual et al. proposed that adjuvant use of 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) mediated PDT and surgery for head and neck squamous cell carcinoma appeared safe. Caesar et al. suggested that m-tetrahydroxyphenylchlorin (mTHPC) mediated PDT may be utilized as adjuvant therapy to surgery in recurrent tumors of the paranasal sinuses and the anterior skull base where complete resection is not achievable. In another study, Doeveren et al. used adjuvant meta-tetrahydroxyphenylchlorin-mediated PDT in patients with a malignancy in the head and neck with close or positive resection margins who were not eligible for conventional treatment modalities and they reported that PDT could be applied as adjuvant therapy after surgery. Wang et al. recently proposed that in prostate cancer, PDT might be an effective adjuvant therapy for image-guided surgery. Friedberg et al. reported that Foscan mediated PDT may be safely combined with surgery at the established maximally tolerated dose. Friedberg et al. conducted a phase II trial in order to investigate the effects of combination of surgery with intraoperative PDT on local control and survival in patients with non-small-cell lung cancer with pleural spread. They reported that surgery and PDT might be performed safely with good local control. Sun et al. suggested that PDT with photofrin on young patients with advanced colorectal cancer could be utilized as an adjuvant therapy. Kuijpers et al. reported four cases of basal cell carcinoma treated with Mohs surgery, where they used PDT with aminolevulinic acid as an adjuvant therapy. The researchers proposed that the combination of Mohs surgery and PDT might result in the cure of the tumor with good cosmetic results. Torres et al. conducted a preliminary study which found that methyl-aminolevulinate mediated PDT can be an alternative as an adjunctive therapy before standard surgical excision of morpheaform basal cell carcinoma. In another study, Nanashima suggested that adjuvant PDT may be a useful option for patients with bile duct carcinoma undergoing surgical resection. Hans-Beat Ris suggested that intraoperative PDT following resection can be an attractive treatment for malignant pleural mesothelioma, which may help to reduce local recurrence.

Photodynamic Therapy Combined With Immunotherapy

PDT may also be utilized in combination with immunotherapy. It has the potential to augment anti-tumor immunity. It is known that generation of effective systemic anti-tumor immune responses has a great potential to eliminate tumors. PDT is capable of inducing immunogenic cell death, which is a cell death modality that stimulates immune responses against dead cell antigens. Furthermore, combining PDT with cancer immunotherapy may demonstrate synergistic results, achieve tumor regression, provide immune memory. In addition to such mechanisms related with immunogenic cell death achieved by PDT, treatment of tumors with infrared laser as a means of autologous vaccination has demonstrated promise in animal studies. Thus, the release of tumor antigens can then play roles as in situ auto-vaccines. Furthermore, proinflammatory cytokines, which stimulate the immune responses, are also increased. As a result of such mechanisms, PDT causes an increased dissemination of tumor antigens and damage associated patterns from the target tumors. The antigens are then taken up by dendritic cells, which subsequently present those antigens to CD4+ and CD8+ T cells. This presentation process results in the activation of adaptive immune responses against the tumor as well as generating immunological memory.

PDT is known to cause inflammation and recruitment of cells such as neutrophils, macrophages. Jalili et al. investigated the effectiveness of combining PDT with administration of dendritic cells. They reported that administration of immature dendritic cells into the tumors treated with PDT caused effective homing to lymph nodes and stimulated T and natural killer cells. Thus, the researchers suggested that combination of PDT and administration of immature dendritic cells might demonstrate a potential for clinical use. In another study, Saji et al. analyzed whether PDT followed by intratumoral administration of naive dendritic cells might stimulate anti-tumor immunity. They reported that PDT and intratumoral injection of dendritic cells resulted in systemic anti-tumor immunity in mice. PDT and low dose cyclophosphamide were shown to generate anti-tumor immunity in a study, which suggested that low dose cyclophosphamide depleted regulatory T cells and potentiated PDT. It was demonstrated that the combination of vinorelbine, PDT with meta-tetrahydroxyphenylchlorin and immune lymphocytes had a significant synergistic anti-tumor effect. In addition, similar results were obtained with the combination of cisplatin, PDT and immune lymphocytes.

Another interesting approach to combine PDT and immunotherapy relies on the generation of cancer vaccines by PDT, since such an approach has a potential to present tumor antigens. The PDT vaccine can be generated ex vivo/in situ. The vaccine can then be administered in order to eliminate tumor cells. Korbelik and Sun generated a whole tumor cell vaccine by in vitro PDT with benzoporphyrin derivative. They proposed that PDT may be utilized in order to generate efficient tumor vaccines. Gollnick et al. investigated PDT-generated murine tumor cell lysates and found that PDT-generated tumor cell lysates could be effective vaccines. In addition, they also reported that such vaccines were more efficient than those generated by UV or ionizing irradiation. Garg et al. combined dendritic cell immunotherapy and immunogenic cell death induced by PDT with hypericin. They suggested that immunogenic cell death based vaccines have the potential for translation to the clinical setting. In another study, Zhang et al. reported that 5-aminolevulinic acid mediated PDT dendritic cell vaccine might stimulate immune responses against tumors. Similarly, Trempolec et al. reported that a PDT dendritic cell vaccine resulted in a considerable increase in IFNγ+ T cells and suggested that PDT dendritic cell vaccines may stimulate anti-tumor immune responses. Korbelik et al. suggested that surgically removed tumor tissues may be utilized for PDT-based vaccines. Such an approach would allow for the customization of therapeutic interventions. Thus, PDT-based vaccines hold the potential for precision medicine applications. Doix et al. investigated the effects of the dose of PS and PDT scheduling on immunity. Their findings suggested that the timing for the administration of PDT dendritic cell vaccine was important, since the administration of the vaccine before radiotherapy failed to increase tumor growth inhibition, whereas administration of the vaccine around/near radiotherapy resulted in considerable delay in tumor growth. A recent study reported that the semisynthetic biopolymer N-dihydrogalactochitosan increased the effectiveness of PDT tumor vaccines. Future studies about tumor vaccine related mechanisms are required, in order to be able to translate such approaches to the clinical use.

The effects of PDT on immune responses may in fact synergize with the effects of immunotherapeutic applications, such as the approaches aimed at attenuating the immune suppression in the tumor milieu via utilizing immune checkpoint inhibitors (e.g., anti-PD-L1, anti-PD-1 and anti-CTLA-4). Mechanisms of immune checkpoint inhibition can be seen in Figure 7. Immune checkpoint inhibition has the potential to induce tumor infiltrating lymphocytes. Given the fact that anti-tumor immune responses may be suppressed due to the effects of tumor cells on T cells via the programmed cell death 1 ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) immune checkpoint axis, PDT mediated cancer immunotherapy may be enhanced through targeting PD-L1 in tumor cells. Wang et al. reported that combining PDT with PD-L1 knockdown demonstrated higher efficiency in terms of suppressing tumor growth and distant metastasis compared to only-PDT in a murine melanoma xenograft model. In another study, Dai et al. showed that PDT combined with PD-L1-blockade siRNA approach can stimulate a PDT-induced immune response and may be effective against immune resistance mediated by PD-L1. He et al. demonstrated that PDT with nanoscale coordination polymer core-shell nanoparticles that carry oxaliplatin in the core and the PS pyropheophorbide-lipid conjugate in the shell combined with anti-PD-L1 suppressed the growth of both primary and distant tumors in murine colorectal cancer models. Duan et al. showed that PDT with Zn-pyrophosphate nanoparticles loaded with the PS pyrolipid sensitized tumors to checkpoint inhibition by a PD-L1 antibody. The approach could eliminate primary breast tumors and prevent lung metastasis. In another study, PDT with Fe-TBP was reported to enhance the efficiency of anti-PD-L1 treatment in a mouse colorectal cancer model. In addition, it induced abscopal effects. Moreover, PDT with Fe-TBP induced tumor cytotoxic T cell infiltration. Moreover, Santos et al. reported a favorable outcome in a clinical case with head and neck cancer, utilizing PDT with Redaporfin followed by an anti-PD-1 antibody.

In addition to the PD-1/PD-L1 axis, blockade of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) checkpoint has also been studied in combination with PDT. Xu et al. reported that an immune-stimulating upconversion nanoparticle-based PDT approach in combination with CTLA-4 checkpoint blockade could effectively target primary tumors and suppress distant tumors, as well as inducing immunological memory. Furthermore, combination of PDT with indoleamine-2,3-dioxygenase (IDO) targeting may also prove to be a useful approach to stimulate immunity; since, IDO is an enzyme which shows an immunosuppressive effect via tryptophan depletion, thereby helping tumors to escape from immunity. In addition, Lu et al. observed higher T cell infiltration in the tumor microenvironment with the combination of IDO inhibition and PDT induced immunogenic cell death. In light of the current literature, the combination of PDT and immunotherapy may not only efficiently eliminate the target tumor; but also can take out tumor cells and metastases. Such an approach can also provide immunological memory to preclude recurrence.

Even though a myriad of studies reported favorable outcomes in in vitro and in vivo investigations, further studies are required for the effective combination of PDT with other therapeutic modalities in the clinic.

Photodynamic Therapy in Different Types of Cancers

As a noninvasive treatment, PDT is mostly utilized for the treatment of nonmelanoma skin cancer as well as precancerous lesions. In addition, PDT may also be utilized in order to treat internal tumors in several parts of the body. Such applications are achieved via administering a systemic PS and then applying specific light via an optical fiber. Indeed, various clinical applications in the fields of dermatology, gastroenterology, neurosurgery, pneumology, gynecology, urology and ophthalmology may demonstrate promising outcomes for the treatment of tumors.

Photodynamic Therapy in Colorectal Cancer

Colorectal cancer is the third most common type of cancer with high invasive character and metastatic potential. Therefore, it constitutes an important clinical issue in which alternative treatments are investigated in addition to conventional therapies. There exist several PDT trials based on ALA and photofrin in colorectal cancer. In addition to these PDT approaches, novel treatment strategies are also being investigated.

The opinion that cancer stem cells are formed due to various genetic or epigenetic changes in adult normal stem cells in the human body has become an important perspective in recent years. In order to achieve this transformation, various genetic mutations and epigenetic modifications should be acquired. Although the cancer stem cell populations differ according to cancer type, they are very scarce (on average 0–2%) in the cancer tissue compared to other cell populations. Increased cancer stem cell proliferation in cancerous tissue shows a positive correlation with cancer’s aggressive character. It is stated that targeting cancer stem cells with PDT-mediated active or passive targeting strategies in colorectal cancer may be an important treatment approach, especially in metastatic colon cancer. In a study conducted on a colon cancer mouse model, it is stated that the cells undergo apoptosis as a result of PDT with chlorin-based nanoscale metal-organic framework. In addition, the combined use of PDT with chemo-radiotherapy may improve overall survival in advanced stage of cholangiocarcinoma.

Photodynamic Therapy in Lung Cancer

Studies on PDT in lung cancer have been carried out for several years. PDT alone was reported to be an important alternative treatment to palliative chemotherapy or radiotherapy in lung cancer. It results in a response rate of approximately 87% as well as improving the patient’s quality of life. In a study conducted on A549 lung cancer cells, PDT mediated with a nanobody complex (Nb@IC-NPs) was able to effectively destruct tumor cells and improve survival in mice. PDT can be used in combination with chemotherapy, radiotherapy and surgery to treat non-small-cell lung cancer. It is proposed that PSs such as temoporfin, 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a, and chlorin e6 demonstrate more favorable toxicity profiles. It was suggested that Photofrin-PDT might be useful as a palliative treatment in lung cancer. However, the efficacy of this method decreases in advanced cancers. It is proposed that current PSs such as talaporfin and HPPH, which have high absorption at longer wavelengths, are more effective than the first-generation photofrin.

Photodynamic Therapy in Prostate Cancer

Prostate cancer is the most frequent cancer in males and it is the second leading cause of cancer death in men in United States. Conventional therapies may cause prominent side effects. For this reason, focal therapies such as cryotherapy or PDT are important. Although padoporfin and motexafin lutetium (MLu) based PDTs may show effective results, it has been noted that PDT approaches used in prostate cancer treatment have various toxic effects. Therefore, it is necessary to revise the treatment strategy by performing dosimetric analyses.

Photodynamic Therapy in Head & Neck Cancer

Head and neck cancer is responsible from more than 650,000 cases and 330,000 deaths annually worldwide. Temoporfin-based PDT can be used as a treatment method in advanced-stage head and neck cancers when surgery and radiotherapy may be insufficient. Photofrin PDT, which is used in patients diagnosed with nasopharyngeal carcinoma and relapsed due to conventional treatments such as fluorouracil and cisplatin, has been reported to be more effective than conventional treatment.

Photodynamic Therapy in Brain Cancer

Malignant gliomas may be fatal tumors. Additionally, post-treatment recurrence rates are approximately 80%. Current treatment strategies result in an overall survival of about 15 months. PSs can be used for both PDD and PDT purposes in brain tumors. It was reported that ALA-based malignant glioma surgery could increase overall survival compared to the control group.

Photodynamic Therapy in Skin Cancer

PDT is frequently used in skin diseases, especially in nonmelanoma skin cancer and precancerous cutaneous lesions. Over 10 million patients have been reported to be treated with PDT so far. PDT is generally preferred in the treatment of actinic keratosis (AK). It was stated that ALA-based PDT is a more effective treatment strategy compared to the cryotherapy used in AK treatment. It was reported that MAL-PDT (methyl aminolevulinate) applied in the treatment of squamous cell carcinoma in situ might achieve 88–100% elimination of the lesions. Although the efficiency of PDT treatment in basal cell carcinoma is similar to cryotherapy and surgical application, PDT provides easy application for difficult areas such as eye lesions.

Photodynamic Therapy in Pancreas Cancer

Pancreas cancer is another type of cancer with high fatality. The 5-years survival in pancreas cancer is less than 10%. Current therapeutic strategies may cause adverse effects. For this reason, various clinical and preclinical trials are ongoing in the setting of pancreas cancer. Phase studies with benzoporphyrin-based PDT in pancreas cancer may yield results associated with low morbidity. Bown et al. utilized PDT with meso-tetrahydroxyphenyl chlorin in pancreas cancer. They reported that PDT could produce necrosis in pancreatic cancers with an acceptable morbidity. In another study, Huggett et al. suggested that Verteporfin PDT-induced tumor necrosis is feasible and safe in locally advanced pancreatic cancer.

Photodynamic Therapy in Breast Cancer

Breast cancer is the most common cancer among women. It demonstrates a complex genetic basis in terms of susceptibility. As a result of the treatment strategies applied for breast cancer, adverse effects and resistance to treatment may occur in some breast cancer subtypes. The new treatment strategies include biomimetic hydrogels encapsulating ROS - sensitive tegafur (TF) and protoporphyrin IX (PpIX) heterodimers (TTP), which aim to utilize chemotherapy and PDT synergistically in order to minimize the side effects that occur during conventional treatment.

Photodynamic Therapy in Cervix Cancer

Cervical cancer is the fourth most common cancer in women. It is estimated that cervical cancer accounted for 604,000 new cancer cases and 342,000 deaths worldwide in 2020. Although conventional treatments have effective responses, cervical stroma is damaged in most patients due to these treatments. In this context, PDT emerges as an effective and harmless treatment strategy. Phase studies with ALA-based PDT in cervical cancer have yielded results associated with low morbidity. A study conducted with HeLa cells showed that cellular uptake increased with phthalocyanine conjugated gold nanoparticles. In addition, the caspase 3/7 pathway was suggested to be activated in the cells as a result of PDT.

Concluding Remarks

Various novel PDT approaches have been studied and developed over the last decades in order to be used against tumors. Preclinical and clinical applications of PDT and PDD have yielded promising results. Topical and systemic administrations of PSs have been utilized in the clinical setting. In addition, several PDT approaches have been approved by major regulatory bodies including the FDA in the United States and the European Medicines Agency (EMA) in Europe. Although we have witnessed a considerable progress in understanding the mechanisms associated with PDT and PDD, the systemic applications of PSs still require further developments. Furthermore, the biophysical features of the constituents of PDT (i.e., PS, light, oxygen) may still represent limitations for the clinical applications of PDT, especially for deep tissue seated hypoxic tumors. Targeted approaches especially in the setting of precision medicine may pave the way for more efficient and widespread utilization of PDT in the clinic. Numerous studies have concentrated on improving the effectiveness and specificity of PDT for specific tumor cells. Such studies demonstrated that various approaches including nanoparticles could be used to achieve such goals. In addition, tumor related cues may also be used as biomarkers. Thus, approaches that target such cues have the potential to improve the specificity of the treatment, as well as decreasing systemic adverse effects. Furthermore, the combination of PDT with other therapeutic modalities such as chemotherapy, immunotherapy, etc. has demonstrated favorable results. Various studies are ongoing in terms of the efforts to determine the optimal combination approaches. Moreover, preclinical interest in designing state-of-the-art PSs for use in PDT or PDD will facilitate the development of more capable and advanced agents. It should also be noted that there are several clinical trials in progress, currently. The importance of the ease of applicability and effectiveness of new treatment modalities in comparison to standard approaches should also be kept in mind. Reasonable strategies may be helpful for clinical translation of novel PDT modalities; thus, allowing for more common use of PDT. In addition to the development of more refined PSs, a better understanding of the effectiveness of PDT in a combination setting in the clinic as well as the optimization of such complex multimodal treatments will expand the clinical applications of PDT.

References 305

  1. 1.

    Abdel-kader M. H. (2016 ). “CHAPTER 1. The Journey of PDT throughout History: PDT from Pharos to Present,” in Photodynamic Medicine. Editors Kostron H. Hasan T. (Cambridge, UK: The Royal Society of Chemistry), 1–21.

    Not in our library10.1039/9781782626824-00001

  2. 2.

    Abrahamse H. Hamblin M. R. (2016 ). New Photosensitizers for Photodynamic Therapy. Biochem. J. 473 (4), 347–364.

    Not in our library10.1042/bj20150942

  3. 3.

    Abrahamse H. Kruger C. A. Kadanyo S. Mishra A. (2017 ). Nanoparticles for Advanced Photodynamic Therapy of Cancer. Photomed. Laser Surg. 35 (11), 581–588.

    Not in our library10.1089/pho.2017.4308

  4. 4.

    Ackroyd R. Kelty C. Brown N. Reed M. (2001 ). The History of Photodetection and Photodynamic Therapy. Photochem. Photobiol. 74 (5), 656–669.

    Not in our library10.1562/0031-8655(2001)074<0656:thopap>2.0.co;2

  5. 5.

    Agostinis P. Berg K. Cengel K. A. Foster T. H. Girotti A. W. Gollnick S. O. (2011 ). Photodynamic Therapy of Cancer: an Update. CA: A Cancer J. Clinicians 61 (4), 250–281.

    Not in our library10.3322/caac.20114

  6. 6.

    Ajani J. A. Song S. Hochster H. S. Steinberg I. B. (2015 ). Cancer Stem Cells: the Promise and the Potential. Semin. Oncol. 42 (Suppl. 1), S3–S17.

    Not in our library10.1053/j.seminoncol.2015.01.001

  7. 7.

    Allison R. R. Moghissi K. (2013a ). Oncologic Photodynamic Therapy: Clinical Strategies that Modulate Mechanisms of Action. Photodiagn. Photodyn. Ther. 10 (4), 331–341.

    Not in our library10.1016/j.pdpdt.2013.03.011

  8. 8.

    Allison R. R. Moghissi K. (2013b ). Photodynamic Therapy (PDT): PDT Mechanisms. Clin. Endosc. 46 (1), 24–29.

    Not in our library10.5946/ce.2013.46.1.24

  9. 9.

    Allison R. R. Downie G. H. Cuenca R. Hu X.-H. Childs C. J. Sibata C. H. (2004 ). Photosensitizers in Clinical PDT. Photodiagn. Photodyn. Ther. 1 (1), 27–42.

    Not in our library10.1016/s1572-1000(04)00007-9

  10. 10.

    Allison R. Moghissi K. Downie G. Dixon K. (2011 ). Photodynamic Therapy (PDT) for Lung Cancer. Photodiagn. Photodyn. Ther. 8 (3), 231–239.

    Not in our library10.1016/j.pdpdt.2011.03.342

  11. 11.

    Allison R. R. (2014 ). Photodynamic Therapy: Oncologic Horizons. Future Oncol. 10 (1), 123–124.

    Not in our library10.2217/fon.13.176

  12. 12.

    Allison R. R. (2016 ). Fluorescence Guided Resection (FGR): A Primer for Oncology. Photodiagn. Photodyn. Ther. 13, 73–80.

    Not in our library10.1016/j.pdpdt.2015.11.008

  13. 13.

    Allman R. Cowburn P. Mason M. (2000 ). Effect of Photodynamic Therapy in Combination with Ionizing Radiation on Human Squamous Cell Carcinoma Cell Lines of the Head and Neck. Br. J. Cancer 83 (5), 655–661.

    Not in our library10.1054/bjoc.2000.1328

  14. 14.

    Alzeibak R. Mishchenko T. A. Shilyagina N. Y. Balalaeva I. V. Vedunova M. V. Krysko D. V. (2021 ). Targeting Immunogenic Cancer Cell Death by Photodynamic Therapy: Past, Present and Future. J. Immunother. Cancer 9 (1), e001926.

    Not in our library10.1136/jitc-2020-001926

  15. 15.
    The role of photodynamic therapy on multidrug resistant breast cancer · 2019
    Not checked
  16. 16.

    Antoni P. M. Naik A. Albert I. Rubbiani R. Gupta S. Ruiz-Sanchez P. (2015 ). (Metallo)porphyrins as Potent Phototoxic Anti-cancer Agents after Irradiation with Red Light. Chem. Eur. J. 21 (3), 1179–1183.

    Not in our library10.1002/chem.201405470

  17. 17.
    Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis · 2020
    Corrected
  18. 18.

    Avendaño C. Menéndez J. C. (2015 ). “Anticancer Drugs Acting via Radical Species,” in Medicinal Chemistry of Anticancer Drugs. Editors Avendaño C. Menéndez J. C. (Boston: Elsevier), 133–195.

    Not in our library10.1016/b978-0-444-62649-3.00004-1

  19. 19.

    Avendano C. Menendez J. (2002 ). Inhibitors of Multidrug Resistance to Antitumor Agents (MDR). Cmc 9 (2), 159–193.

    Not in our library10.2174/0929867023371175

  20. 20.

    Ayan S. Gunaydin G. Yesilgul-Mehmetcik N. Gedik M. E. Seven O. Akkaya E. U. (2020 ). Proof-of-principle for Two-Stage Photodynamic Therapy: Hypoxia Triggered Release of Singlet Oxygen. Chem. Commun. 56 (94), 14793–14796.

    Not in our library10.1039/d0cc06031c

  21. 21.

    Bai D. Xia X. Yow C. M. N. Chu E. S. M. Xu C. (2011 ). Hypocrellin B-Encapsulated Nanoparticle-Mediated Rev-Caspase-3 Gene Transfection and Photodynamic Therapy on Tumor Cells. Eur. J. Pharmacol. 650 (2-3), 496–500.

    Not in our library10.1016/j.ejphar.2010.10.017

  22. 22.

    Barras A. Skandrani N. Gonzalez Pisfil M. Paryzhak S. Dumych T. Haustrate A. (2018 ). Improved Photodynamic Effect through Encapsulation of Two Photosensitizers in Lipid Nanocapsules. J. Mater. Chem. B 6 (37), 5949–5963.

    Not in our library10.1039/c8tb01759j

  23. 23.
    Clinical development of photodynamic agents and therapeutic applications · 2018
    No notice
  24. 24.

    Bazylińska U. Pietkiewicz J. Saczko J. Nattich-Rak M. Rossowska J. Garbiec A. (2012 ). Nanoemulsion-templated Multilayer Nanocapsules for Cyanine-type Photosensitizer Delivery to Human Breast Carcinoma Cells. Eur. J. Pharm. Sci. 47 (2), 406–420.

    Not in our library10.1016/j.ejps.2012.06.019

  25. 25.

    Beharry A. A. (2018 ). Next-Generation Photodynamic Therapy: New Probes for Cancer Imaging and Treatment. Biochemistry 57 (2), 173–174.

    Not in our library10.1021/acs.biochem.7b01037

  26. 26.

    Bhandari V. Hoey C. Liu L. Y. Lalonde E. Ray J. Livingstone J. (2019 ). Molecular Landmarks of Tumor Hypoxia across Cancer Types. Nat. Genet. 51 (2), 308–318.

    Not in our library10.1038/s41588-018-0318-2

  27. 27.

    Bhuvaneswari R. Yuen G. Y. Chee S. K. Olivo M. (2007 ). Hypericin-mediated Photodynamic Therapy in Combination with Avastin (Bevacizumab) Improves Tumor Response by Downregulating Angiogenic Proteins. Photochem. Photobiol. Sci. 6 (12), 1275–1283.

    Not in our library10.1039/b705763f

  28. 28.

    Bhuvaneswari R. Gan Y. Y. Soo K. C. Olivo M. (2009 ). The Effect of Photodynamic Therapy on Tumor Angiogenesis. Cell. Mol. Life Sci. 66 (14), 2275–2283.

    Not in our library10.1007/s00018-009-0016-4

  29. 29.

    Bolze F. Jenni S. Sour A. Heitz V. (2017 ). Molecular Photosensitisers for Two-Photon Photodynamic Therapy. Chem. Commun. 53 (96), 12857–12877.

    Not in our library10.1039/c7cc06133a

  30. 30.

    Bonavida B. Chouaib S. (2017 ). Resistance to Anticancer Immunity in Cancer Patients: Potential Strategies to Reverse Resistance. Ann. Oncol. 28 (3), 457–467.

    Not in our library10.1093/annonc/mdw615

  31. 31.

    Borgia F. Giuffrida R. Caradonna E. Vaccaro M. Guarneri F. Cannavo S. P. (2018 ). Early and Late Onset Side Effects of Photodynamic Therapy. Biomedicines 6 (1), 12.

    Not in our library10.3390/biomedicines6010012

  32. 32.

    Bown S. G. Rogowska A. Z. Whitelaw D. E. Lees W. R. Lovat L. B. Ripley P. (2002 ). Photodynamic Therapy for Cancer of the Pancreas. Gut 50 (4), 549–557.

    Not in our library10.1136/gut.50.4.549

  33. 33.

    Brackett C. M. Gollnick S. O. (2011 ). Photodynamic Therapy Enhancement of Anti-tumor Immunity. Photochem. Photobiol. Sci. 10 (5), 649–652.

    Not in our library10.1039/c0pp00354a

  34. 34.

    Brancaleon L. Moseley H. (2002 ). Laser and Non-laser Light Sources for Photodynamic Therapy. Lasers Med. Sci. 17 (3), 173–186.

    Not in our library10.1007/s101030200027

  35. 35.

    Bray F. Ferlay J. Soerjomataram I. Siegel R. L. Torre L. A. Jemal A. (2018 ). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer J. Clinicians 68 (6), 394–424.

    Not in our library10.3322/caac.21492

  36. 36.

    Brown S. B. Brown E. A. Walker I. (2004 ). The Present and Future Role of Photodynamic Therapy in Cancer Treatment. Lancet Oncol. 5 (8), 497–508.

    Not in our library10.1016/s1470-2045(04)01529-3

  37. 37.

    Bryan C. P. t. (1930 ). The Papyrus Ebers/Translated from the German Version by Cyril P. Bryan... With an Introduction by Professor J. Elliot Smith. London: G. Bles.

    Not in our library

  38. 38.

    Bugaj A. M. (2011 ). Targeted Photodynamic Therapy - a Promising Strategy of Tumor Treatment. Photochem. Photobiol. Sci. 10 (7), 1097–1109.

    Not in our library10.1039/c0pp00147c

  39. 39.

    Burstein H. J. (2005 ). The Distinctive Nature of HER2-Positive Breast Cancers. N. Engl. J. Med. 353 (16), 1652–1654.

    Not in our library10.1056/nejmp058197

  40. 40.

    Caesar L. van Doeveren T. E. M. Tan I. B. Dilci A. van Veen R. L. P. Karakullukcu B. (2015 ). The Use of Photodynamic Therapy as Adjuvant Therapy to Surgery in Recurrent Malignant Tumors of the Paranasal Sinuses. Photodiagn. Photodyn. Ther. 12 (3), 414–421.

    Not in our library10.1016/j.pdpdt.2015.06.001

  41. 41.

    Canti G. Nicolin A. Cubeddu R. Taroni P. Bandieramonte G. Valentini G. (1998 ). Antitumor Efficacy of the Combination of Photodynamic Therapy and Chemotherapy in Murine Tumors. Cancer Lett. 125 (1-2), 39–44.

    Not in our library10.1016/s0304-3835(97)00502-8

  42. 42.

    Canti G. Calastretti A. Bevilacqua A. Reddi E. Palumbo G. Nicolin A. (2010 ). Combination of Photodynamic Therapy + Immunotherapy + Chemotherapy in Murine Leukiemia. neo 57 (2), 184–188.

    Not in our library10.4149/neo_2010_02_184

  43. 43.

    Carmeliet P. Jain R. K. (2011 ). Principles and Mechanisms of Vessel Normalization for Cancer and Other Angiogenic Diseases. Nat. Rev. Drug Discov. 10 (6), 417–427.

    Not in our library10.1038/nrd3455

  44. 44.

    Castano A. P. Demidova T. N. Hamblin M. R. (2005 ). Mechanisms in Photodynamic Therapy: Part Three-Photosensitizer Pharmacokinetics, Biodistribution, Tumor Localization and Modes of Tumor Destruction. Photodiagnosis Photodynamic Ther. 2 (2), 91–106.

    Not in our library10.1016/s1572-1000(05)00060-8

  45. 45.

    Castano A. P. Mroz P. Hamblin M. R. (2006 ). Photodynamic Therapy and Anti-tumour Immunity. Nat. Rev. Cancer 6 (7), 535–545.

    Not in our library10.1038/nrc1894

  46. 46.

    Castano A. P. Mroz P. Wu M. X. Hamblin M. R. (2008 ). Photodynamic Therapy Plus Low-Dose Cyclophosphamide Generates Antitumor Immunity in a Mouse Model. Proc. Natl. Acad. Sci. 105 (14), 5495–5500.

    Not in our library10.1073/pnas.0709256105

  47. 47.

    Ceglia L. Toni R. (2018 ). “Vitamin D and Muscle Performance in Athletes,” in Vitamin D and Muscle Performance in Athletes. Editor Feldman D. (Academic Press), 1121–1130.

    Not in our library10.1016/b978-0-12-809963-6.00113-9

  48. 48.

    Chaffer C. L. Weinberg R. A. (2011 ). A Perspective on Cancer Cell Metastasis. Science 331 (6024), 1559–1564.

    Not in our library10.1126/science.1203543

  49. 49.

    Chen W. R. Zhu W.-G. Dynlacht J. R. Liu H. Nordquist R. E. (1999 ). Long-term Tumor Resistance Induced by Laser Photo-Immunotherapy. Int. J. Cancer 81 (5), 808–812.

    Not in our library10.1002/(sici)1097-0215(19990531)81:5<808::aid-ijc23>3.0.co;2-j

  50. 50.

    Chen W. R. Singhal A. K. Liu H. Nordquist R. E. (2001 ). Antitumor Immunity Induced by Laser Immunotherapy and its Adoptive Transfer. Cancer Res. 61 (2), 459–461.

    Not in our library

  51. 51.

    Chen W. R. Jeong S. W. Lucroy M. D. Wolf R. F. Howard E. W. Liu H. (2003 ). Induced Antitumor Immunity against DMBA-4 Metastatic Mammary Tumors in Rats Using Laser Immunotherapy. Int. J. Cancer 107 (6), 1053–1057.

    Not in our library10.1002/ijc.11501

  52. 52.

    Chen Q. Wen J. Li H. Xu Y. Liu F. Sun S. (2016 ). Recent Advances in Different Modal Imaging-Guided Photothermal Therapy. Biomaterials 106, 144–166.

    Not in our library10.1016/j.biomaterials.2016.08.022

  53. 53.

    Chien C.-T. Yan J.-Y. Chiu W.-C. Wu T.-H. Liu C.-Y. Lin S.-Y. (2013 ). Caged Pt Nanoclusters Exhibiting Corrodibility to Exert Tumor-Inside Activation for Anticancer Chemotherapeutics. Adv. Mater. 25 (36), 5067–5073.

    Not in our library10.1002/adma.201302363

  54. 54.

    Chilakamarthi U. Giribabu L. (2017 ). Photodynamic Therapy: Past, Present and Future. Chem. Rec. 17 (8), 775–802.

    Not in our library10.1002/tcr.201600121

  55. 55.

    Clarke C. P. Knight S. R. Daniel F. J. Seevanayagam S. (2006 ). Management of Malignant Mesothelioma by Decortication and Adjunct Phototherapy. Asian Cardiovasc. Thorac. Ann. 14 (3), 206–209.

    Not in our library10.1177/021849230601400307

  56. 56.

    Cramer G. M. Moon E. K. Cengel K. A. Busch T. M. (2020 ). Photodynamic Therapy and Immune Checkpoint Blockade †. Photochem. Photobiol. 96 (5), 954–961.

    Not in our library10.1111/php.13300

  57. 57.

    Cramers P. Ruevekamp M. Oppelaar H. Dalesio O. Baas P. Stewart F. A. (2003 ). Foscan Uptake and Tissue Distribution in Relation to Photodynamic Efficacy. Br. J. Cancer 88 (2), 283–290.

    Not in our library10.1038/sj.bjc.6600682

  58. 58.

    Dąbrowski J. M. Arnaut L. G. (2015 ). Photodynamic Therapy (PDT) of Cancer: from Local to Systemic Treatment. Photochem. Photobiol. Sci. 14 (10), 1765–1780.

    Not in our library10.1039/c5pp00132c

  59. 59.

    Dai L. Li K. Li M. Zhao X. Luo Z. Lu L. (2018 ). Size/Charge Changeable Acidity-Responsive Micelleplex for Photodynamic-Improved PD-L1 Immunotherapy with Enhanced Tumor Penetration. Adv. Funct. Mater. 28 (18), 1707249.

    Not in our library10.1002/adfm.201707249

  60. 60.

    Dalerba P. Cho R. W. Clarke M. F. (2007 ). Cancer Stem Cells: Models and Concepts. Annu. Rev. Med. 58, 267–284.

    Not in our library10.1146/annurev.med.58.062105.204854

  61. 61.

    Daniell M. D. Hill J. S. (1991 ). A History of Photodynamic Therapy. ANZ J. Surg. 61 (5), 340–348.

    Not in our library10.1111/j.1445-2197.1991.tb00230.x

  62. 62.
    Immune checkpoint inhibitors: recent progress and potential biomarkers · 2018
    No notice
  63. 63.

    Dave D. Desai U. Despande N. Yadav N. (2012 ). Photodynamic Therapy: A View through Light. Jofr 2, 82–86.

    Not in our library10.5005/jp-journals-10026-1019

  64. 64.

    Davis A. Tinker A. V. Friedlander M. (2014 ). "Platinum Resistant" Ovarian Cancer: What Is it, Who to Treat and How to Measure Benefit? Gynecol. Oncol. 133 (3), 624–631.

    Not in our library10.1016/j.ygyno.2014.02.038

  65. 65.

    DeBerardinis R. J. Lum J. J. Hatzivassiliou G. Thompson C. B. (2008 ). The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation. Cel Metab. 7 (1), 11–20.

    Not in our library10.1016/j.cmet.2007.10.002

  66. 66.

    Dobson J. de Queiroz G. F. Golding J. P. (2018 ). Photodynamic Therapy and Diagnosis: Principles and Comparative Aspects. Vet. J. 233, 8–18.

    Not in our library10.1016/j.tvjl.2017.11.012

  67. 67.

    Doix B. Trempolec N. Riant O. Feron O. (2019 ). Low Photosensitizer Dose and Early Radiotherapy Enhance Antitumor Immune Response of Photodynamic Therapy-Based Dendritic Cell Vaccination. Front. Oncol. 9, 811.

    Not in our library10.3389/fonc.2019.00811

  68. 68.

    Dolmans D. E. J. G. J. Fukumura D. Jain R. K. (2003 ). Photodynamic Therapy for Cancer. Nat. Rev. Cancer 3 (5), 380–387.

    Not in our library10.1038/nrc1071

  69. 69.

    Dos Santos A. l. F. De Almeida D. R. Q. Terra L. F. Baptista M. c. S. Labriola L. (2019 ). Photodynamic Therapy in Cancer Treatment - an Update Review. Jcmt 2019, 25.

    Not in our library10.20517/2394-4722.2018.83

  70. 70.

    Dougherty T. J. Gomer C. J. Henderson B. W. Jori G. Kessel D. Korbelik M. (1998 ). Photodynamic Therapy. JNCI J. Natl. Cancer Inst. 90 (12), 889–905.

    Not in our library10.1093/jnci/90.12.889

  71. 71.

    Dougherty T. J. (1996 ). A Brief History of Clinical Photodynamic Therapy Development at Roswell Park Cancer Institute. J. Clin. Laser Med. Surg. 14 (5), 219–221.

    Not in our library10.1089/clm.1996.14.219

  72. 72.

    Duan X. Chan C. Guo N. Han W. Weichselbaum R. R. Lin W. (2016 ). Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade to Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. J. Am. Chem. Soc. 138 (51), 16686–16695.

    Not in our library10.1021/jacs.6b09538

  73. 73.

    Duchi S. Sotgiu G. Lucarelli E. Ballestri M. Dozza B. Santi S. (2013 ). Mesenchymal Stem Cells as Delivery Vehicle of Porphyrin Loaded Nanoparticles: Effective Photoinduced In Vitro Killing of Osteosarcoma. J. Controlled Release 168 (2), 225–237.

    Not in our library10.1016/j.jconrel.2013.03.012

  74. 74.

    DUSA (2018 ). Levulan Kerastick (Aminolevulinic Acid HCl) [package Insert]. U.S. Food and Drug Administration Website. Revised April 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020965s016lbl.pdf. (Accessed Mar 14, 2021).

    Not in our library

  75. 75.

    Ebers G. (1875 ). Papyros Ebers: Das Hermetische Buch über die Arzneimittel der alten Ägypter in hieratischer Schrift (Band 1): Einleitung und Text. Leipzig: Verlag von Wilhelm Engelmann.

    Not in our library

  76. 76.

    Eccles S. A. (2011 ). The Epidermal Growth Factor receptor/Erb-B/HER Family in normal and Malignant Breast Biology. Int. J. Dev. Biol. 55 (7-9), 685–696.

    Not in our library10.1387/ijdb.113396se

  77. 77.

    Eppert K. Takenaka K. Lechman E. R. Waldron L. Nilsson B. van Galen P. (2011 ). Stem Cell Gene Expression Programs Influence Clinical Outcome in Human Leukemia. Nat. Med. 17 (9), 1086–1093.

    Not in our library10.1038/nm.2415

  78. 78.

    Esim O. Gedik M. E. Dogan A. L. Gunaydin G. Hascicek C. (2021 ). Development of Carboplatin Loaded Bovine Serum Albumin Nanoparticles and Evaluation of its Effect on an Ovarian Cancer Cell Line. J. Drug Deliv. Sci. Technol. 64, 102655.

    Not in our library10.1016/j.jddst.2021.102655

  79. 79.

    Fan W. Huang P. Chen X. (2016 ). Overcoming the Achilles' Heel of Photodynamic Therapy. Chem. Soc. Rev. 45 (23), 6488–6519.

    Not in our library10.1039/c6cs00616g

  80. 80.

    Fasiku V. K. Amuhaya E. M. Rajab K. A. Omolo C. (2021, Nano/Microparticles Encapsulation via Covalent Drug Conjugation London, UK: IntechOpen.

    Not in our library10.5772/intechopen.93364

  81. 81.

    Ferrario A. Gomer C. (2006 ). Avastin Enhances Photodynamic Therapy Treatment of Kaposi's Sarcoma in a Mouse Tumor Model. J. Environ. Pathol. Toxicol. Oncol. 25 (1-2), 251–260.

    Not in our library10.1615/jenvironpatholtoxicoloncol.v25.i1-2.160

  82. 82.

    Ferrario A. von Tiehl K. F. Rucker N. Schwarz M. A. Gill P. S. Gomer C. J. (2000 ). Antiangiogenic Treatment Enhances Photodynamic Therapy Responsiveness in a Mouse Mammary Carcinoma. Cancer Res. 60 (15), 4066–4069.

    Not in our library

  83. 83.

    Firczuk M. Winiarska M. Szokalska A. Jodlowska M. Swiech M. Bojarczuk K. (2011 ). Approaches to Improve Photodynamic Therapy of Cancer. Front. Biosci. 16, 208–224.

    Not in our library10.2741/3684

  84. 84.

    Fitzpatrick T. B. Pathak M. A. (1959 ). Part IV: Basic Considerations of the Psoralens: Historical Aspects of Methoxsalen and Other Furocoumarins11From the Division of Dermatology, University of Oregon Medical School, Portland, Oregon. J. Invest. Dermatol. 32 (2), 229–231.

    Not in our library10.1038/jid.1959.40

  85. 85.

    Fleshker S. Preise D. Kalchenko V. Scherz A. Salomon Y. (2008 ). Prompt Assessment of WST11-VTP Outcome Using Luciferase Transfected Tumors Enables Second Treatment and Increase in Overall Therapeutic Rate. Photochem. Photobiol. 84 (5), 1231–1237.

    Not in our library10.1111/j.1751-1097.2008.00340.x

  86. 86.

    Freitas L. F. Hamblin M. (2016 ). Chapter 1 - Antimicrobial Photoinactivation with Functionalized Fullerenes. Nanobiomater. Antimicrob. Ther., 1–27.

    Not in our library10.1016/b978-0-323-42864-4.00001-4

  87. 87.

    Friedberg J. S. Mick R. Stevenson J. Metz J. Zhu T. Buyske J. (2003 ). A Phase I Study of Foscan-Mediated Photodynamic Therapy and Surgery in Patients with Mesothelioma. Ann. Thorac. Surg. 75 (3), 952–959.

    Not in our library10.1016/s0003-4975(02)04474-0

  88. 88.

    Friedberg J. S. Mick R. Stevenson J. P. Zhu T. Busch T. M. Shin D. (2004 ). Phase II Trial of Pleural Photodynamic Therapy and Surgery for Patients with Non-small-cell Lung Cancer with Pleural Spread. Jco 22 (11), 2192–2201.

    Not in our library10.1200/jco.2004.07.097

  89. 89.

    Fukuhara H. Yamamoto S. Karashima T. Inoue K. (2021 ). Photodynamic Diagnosis and Therapy for Urothelial Carcinoma and Prostate Cancer: New Imaging Technology and Therapy. Int. J. Clin. Oncol. 26 (1), 18–25.

    Not in our library10.1007/s10147-020-01704-y

  90. 90.

    Furuse K. Fukuoka M. Kato H. Horai T. Kubota K. Kodama N. (1993 ). A Prospective Phase II Study on Photodynamic Therapy with Photofrin II for Centrally Located Early-Stage Lung Cancer. The Japan Lung Cancer Photodynamic Therapy Study Group. Jco 11 (10), 1852–1857.

    Not in our library10.1200/jco.1993.11.10.1852

  91. 91.

    Galderma Labs LP (2012 ). Gleolan (Aminolevulinic Acid Hydrochloride) [package Insert]. U.S. Food and Drug Administration Website. Revised November 2012. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021415s004lbl.pdf. (Accessed Mar 14, 2021).

    Not in our library

  92. 92.

    Gan J. Li S. Meng Y. Liao Y. Jiang M. Qi L. (2020 ). The Influence of Photodynamic Therapy on the Warburg Effect in Esophageal Cancer Cells. Lasers Med. Sci. 35 (8), 1741–1750.

    Not in our library10.1007/s10103-020-02966-8

  93. 93.

    Garcia-Zuazaga J. Cooper K. D. Baron E. D. (2005 ). Photodynamic Therapy in Dermatology: Current Concepts in the Treatment of Skin Cancer. Expert Rev. Anticancer Ther. 5 (5), 791–800.

    Not in our library10.1586/14737140.5.5.791

  94. 94.

    Garg A. D. Vandenberk L. Koks C. Verschuere T. Boon L. Van Gool S. W. (2016 ). Dendritic Cell Vaccines Based on Immunogenic Cell Death Elicit Danger Signals and T Cell-Driven Rejection of High-Grade Glioma. Sci. Transl. Med. 8 (328), 328ra27.

    Not in our library10.1126/scitranslmed.aae0105

  95. 95.

    Gatenby R. A. Gillies R. J. (2004 ). Why Do Cancers Have High Aerobic Glycolysis? Nat. Rev. Cancer 4 (11), 891–899.

    Not in our library10.1038/nrc1478

  96. 96.

    Gheewala T. Skwor T. Munirathinam G. (2017 ). Photosensitizers in Prostate Cancer Therapy. Oncotarget 8 (18), 30524–30538.

    Not in our library10.18632/oncotarget.15496

  97. 97.

    Gilkes D. M. Semenza G. L. Wirtz D. (2014 ). Hypoxia and the Extracellular Matrix: Drivers of Tumour Metastasis. Nat. Rev. Cancer 14 (6), 430–439.

    Not in our library10.1038/nrc3726

  98. 98.

    Gillet J.-P. Gottesman M. M. (2010 ). Mechanisms of Multidrug Resistance in Cancer. Methods Mol. Biol. 596, 47–76.

    Not in our library10.1007/978-1-60761-416-6_4

  99. 99.

    Gogvadze V. Orrenius S. Zhivotovsky B. (2008 ). Mitochondria in Cancer Cells: what Is So Special about Them? Trends Cel Biol. 18 (4), 165–173.

    Not in our library10.1016/j.tcb.2008.01.006

  100. 100.
    Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs · 2019
    No notice
  101. 101.

    Goldberg B. (1930 ). Heliotherapy. Arch. Phys. Ther. 11, 263.

    Not in our library

  102. 102.

    Gollnick S. O. Vaughan L. Henderson B. W. (2002 ). Generation of Effective Antitumor Vaccines Using Photodynamic Therapy. Cancer Res. 62 (6), 1604–1608.

    Not in our library

  103. 103.

    Gomer C. J. (1991 ). Preclinical Examination of First and Second Generation Photosensitizers Used in Photodynamic Therapy. Photochem. Photobiol. 54 (6), 1093–1107.

    Not in our library10.1111/j.1751-1097.1991.tb02133.x

  104. 104.

    Gonzalez H. Hagerling C. Werb Z. (2018 ). Roles of the Immune System in Cancer: from Tumor Initiation to Metastatic Progression. Genes Dev. 32 (19-20), 1267–1284.

    Not in our library10.1101/gad.314617.118

  105. 105.

    Green D. R. Ferguson T. Zitvogel L. Kroemer G. (2009 ). Immunogenic and Tolerogenic Cell Death. Nat. Rev. Immunol. 9 (5), 353–363.

    Not in our library10.1038/nri2545

  106. 106.

    Gross S. Gilead A. Scherz A. Neeman M. Salomon Y. (2003 ). Monitoring Photodynamic Therapy of Solid Tumors Online by BOLD-Contrast MRI. Nat. Med. 9 (10), 1327–1331.

    Not in our library10.1038/nm940

  107. 107.

    Grzybowski A. Sak J. Pawlikowski J. (2016 ). A Brief Report on the History of Phototherapy. Clin. Dermatol. 34 (5), 532–537.

    Not in our library10.1016/j.clindermatol.2016.05.002

  108. 108.

    Gunaydin G. Gedik M. E. (2019 ). Effects of Cellular Energy Homeostasis Modulation through AMPK on Regulation of Protein Translation and Response to Hypoxia. Turkish J. Biochem. 44 (5), 611–620.

    Not in our library10.1515/tjb-2018-0338

  109. 109.

    Gunaydin G. Kesikli S. A. Guc D. (2015 ). Cancer Associated Fibroblasts Have Phenotypic and Functional Characteristics Similar to the Fibrocytes that Represent a Novel MDSC Subset. Oncoimmunology 4 (9), e1034918.

    Not in our library10.1080/2162402x.2015.1034918

  110. 110.
    Photodynamic Therapy—Current Limitations and Novel Approaches · 2021
    No notice
  111. 111.
    CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion · 2021
    No notice
  112. 112.

    Gupta S. Mishra A. K. Muralidhar K. Jain V. (2004 ). Improved Targeting of Photosensitizers by Intratumoral Administration of Immunoconjugates. Technol. Cancer Res. Treat. 3 (3), 295–301.

    Not in our library10.1177/153303460400300307

  113. 113.

    Haider M. A. Davidson S. R. H. Kale A. V. Weersink R. A. Evans A. J. Toi A. (2007 ). Prostate Gland: MR Imaging Appearance after Vascular Targeted Photodynamic Therapy with Palladium-Bacteriopheophorbide. Radiology 244 (1), 196–204.

    Not in our library10.1148/radiol.2441060398

  114. 114.

    Hamblin M. R. Hasan T. (2004 ). Photodynamic Therapy: a New Antimicrobial Approach to Infectious Disease? Photochem. Photobiol. Sci. 3 (5), 436–450.

    Not in our library10.1039/b311900a

  115. 115.

    Hamblin M. R. (2018 ). Fullerenes as Photosensitizers in Photodynamic Therapy: Pros and Cons. Photochem. Photobiol. Sci. 17 (11), 1515–1533.

    Not in our library10.1039/c8pp00195b

  116. 116.

    Han Y. Liu D. Li L. (2020 ). PD-1/PD-L1 Pathway: Current Researches in Cancer. Am. J. Cancer Res. 10 (3), 727–742.

    Not in our library

  117. 117.

    Hartmann A. (2016 ). Back to the Roots - Dermatology in Ancient Egyptian Medicine. JDDG: J. der Deutschen Dermatologischen Gesellschaft 14 (4), 389–396.

    Not in our library10.1111/ddg.12947

  118. 118.
    Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy · 2016
    No notice
  119. 119.

    Hefti M. Maximilian Mehdorn H. Albert I. Dorner L. (2010 ). Fluorescence-Guided Surgery for Malignant Glioma: A Review on Aminolevulinic Acid Induced Protoporphyrin IX Photodynamic Diagnostic in Brain Tumors. Cmir 6 (4), 254–258.

    Not in our library10.2174/157340510793205503

  120. 120.

    Hester S. C. Kuriakose M. Nguyen C. D. Mallidi S. (2020 ). Role of Ultrasound and Photoacoustic Imaging in Photodynamic Therapy for Cancer. Photochem. Photobiol. 96 (2), 260–279.

    Not in our library10.1111/php.13217

  121. 121.

    Hiam-Galvez K. J. Allen B. M. Spitzer M. H. (2021 ). Systemic Immunity in Cancer. Nat. Rev. Cancer 21 (6), 345–359.

    Not in our library10.1038/s41568-021-00347-z

  122. 122.

    Hodgkinson N. Kruger C. A. Abrahamse H. (2017 ). Targeted Photodynamic Therapy as Potential Treatment Modality for the Eradication of colon Cancer and colon Cancer Stem Cells. Tumour Biol. 39 (10), 101042831773469.

    Not in our library10.1177/1010428317734691

  123. 123.

    Hönigsmann H. (2013 ). History of Phototherapy in Dermatology. Photochem. Photobiol. Sci. 12 (1), 16–21.

    Not in our library10.1039/c2pp25120e

  124. 124.

    Huang Z. Haider M. A. Kraft S. Chen Q. Blanc D. Wilson B. C. (2006 ). Magnetic Resonance Imaging Correlated with the Histopathological Effect of Pd-Bacteriopheophorbide (Tookad) Photodynamic Therapy on the normal Canine Prostate Gland. Lasers Surg. Med. 38 (7), 672–681.

    Not in our library10.1002/lsm.20375

  125. 125.

    Huang Z. (2005 ). A Review of Progress in Clinical Photodynamic Therapy. Technol. Cancer Res. Treat. 4 (3), 283–293.

    Not in our library10.1177/153303460500400308

  126. 126.

    Hudson R. Carcenac M. Smith K. Madden L. Clarke O. J. Pèlegrin A. (2005 ). The Development and Characterisation of Porphyrin Isothiocyanate-Monoclonal Antibody Conjugates for Photoimmunotherapy. Br. J. Cancer 92 (8), 1442–1449.

    Not in our library10.1038/sj.bjc.6602517

  127. 127.

    Huggett M. T. Jermyn M. Gillams A. Illing R. Mosse S. Novelli M. (2014 ). Phase I/II Study of Verteporfin Photodynamic Therapy in Locally Advanced Pancreatic Cancer. Br. J. Cancer 110 (7), 1698–1704.

    Not in our library10.1038/bjc.2014.95

  128. 128.

    Inoue K. (2017 ). 5-Aminolevulinic Acid-Mediated Photodynamic Therapy for Bladder Cancer. Int. J. Urol. 24 (2), 97–101.

    Not in our library10.1111/iju.13291

  129. 129.
    Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications · 2014
    No notice
  130. 130.

    Islam F. Qiao B. Smith R. A. Gopalan V. Lam A. K.-Y. (2015 ). Cancer Stem Cell: Fundamental Experimental Pathological Concepts and Updates. Exp. Mol. Pathol. 98 (2), 184–191.

    Not in our library10.1016/j.yexmp.2015.02.002

  131. 131.

    Jalili A. Makowski M. Świtaj T. Nowis D. Wilczyński G. M. Wilczek E. (2004 ). Effective Photoimmunotherapy of Murine colon Carcinoma Induced by the Combination of Photodynamic Therapy and Dendritic Cells. Clin. Cancer Res. 10 (13), 4498–4508.

    Not in our library10.1158/1078-0432.ccr-04-0367

  132. 132.

    Jankun J. Keck R. W. Skrzypczak-Jankun E. Lilge L. Selman S. H. (2005 ). Diverse Optical Characteristic of the Prostate and Light Delivery System: Implications for Computer Modelling of Prostatic Photodynamic Therapy. BJU Int. 95 (9), 1237–1244.

    Not in our library10.1111/j.1464-410x.2005.05512.x

  133. 133.

    Jiang F. Zhang X. Kalkanis S. N. Zhang Z. Yang H. Katakowski M. (2008 ). Combination Therapy with Antiangiogenic Treatment and Photodynamic Therapy for the Nude Mouse Bearing U87 Glioblastoma. Photochem. Photobiol. 84 (1), 128–137.

    Not in our library10.1111/j.1751-1097.2007.00208.x

  134. 134.
    The updated landscape of tumor microenvironment and drug repurposing · 2020
    No notice
  135. 135.

    Jin M. L. Yang B. Q. Zhang W. Ren P. (1992 ). Combined Treatment with Photodynamic Therapy and Chemotherapy for Advanced Cardiac Cancers. J. Photochem. Photobiol. B: Biol. 12 (1), 101–106.

    Not in our library10.1016/1011-1344(92)85021-l

  136. 136.

    Jori G. Fabris C. Soncin M. Ferro S. Coppellotti O. Dei D. (2006 ). Photodynamic Therapy in the Treatment of Microbial Infections: Basic Principles and Perspective Applications. Lasers Surg. Med. 38 (5), 468–481.

    Not in our library10.1002/lsm.20361

  137. 137.

    Jori G. (2006 ). Photodynamic Therapy of Microbial Infections: State of the Art and Perspectives. J. Environ. Pathol. Toxicol. Oncol. 25 (1-2), 505–520.

    Not in our library10.1615/jenvironpatholtoxicoloncol.v25.i1-2.320

  138. 138.

    Josefsen L. B. Boyle R. W. (2008 ). Photodynamic Therapy: Novel Third-Generation Photosensitizers One Step Closer? Br. J. Pharmacol. 154 (1), 1–3.

    Not in our library10.1038/bjp.2008.98

  139. 139.

    Juarranz Á. Jaén P. Sanz-Rodríguez F. Cuevas J. González S. (2008 ). Photodynamic Therapy of Cancer. Basic Principles and Applications. Clin. Transl Oncol. 10 (3), 148–154.

    Not in our library10.1007/s12094-008-0172-2

  140. 140.

    Juzeniene A. Peng Q. Moan J. (2007 ). Milestones in the Development of Photodynamic Therapy and Fluorescence Diagnosis. Photochem. Photobiol. Sci. 6 (12), 1234–1245.

    Not in our library10.1039/b705461k

  141. 141.

    Kallioniemi O. P. Kallioniemi A. Kurisu W. Thor A. Chen L. C. Smith H. S. (1992 ). ERBB2 Amplification in Breast Cancer Analyzed by Fluorescence In Situ Hybridization. Proc. Natl. Acad. Sci. 89 (12), 5321–5325.

    Not in our library10.1073/pnas.89.12.5321

  142. 142.

    Karaman O. Almammadov T. Emre Gedik M. Gunaydin G. Kolemen S. Gunbas G. (2019 ). Mitochondria‐Targeting Selenophene‐Modified BODIPY‐Based Photosensitizers for the Treatment of Hypoxic Cancer Cells. ChemMedChem 14 (22), 1879–1886.

    Not in our library10.1002/cmdc.201900380

  143. 143.

    Karges J. Tharaud M. Gasser G. (2021 ). Polymeric Encapsulation of a Ru(II)-Based Photosensitizer for Folate-Targeted Photodynamic Therapy of Drug Resistant Cancers. J. Med. Chem. 64 (8), 4612–4622.

    Not in our library10.1021/acs.jmedchem.0c02006

  144. 144.

    Kästle M. Grimm S. Nagel R. Breusing N. Grune T. (2011 ). Combination of PDT and Inhibitor Treatment Affects Melanoma Cells and Spares Keratinocytes. Free Radic. Biol. Med. 50 (2), 305–312.

    Not in our library10.1016/j.freeradbiomed.2010.11.012

  145. 145.

    Kataoka H. Nishie H. Hayashi N. Tanaka M. Nomoto A. Yano S. (2017 ). New Photodynamic Therapy with Next-Generation Photosensitizers. Ann. Transl. Med. 5 (8), 183.

    Not in our library10.21037/atm.2017.03.59

  146. 146.

    Kato H. (2004 ). The History of the Study of Photodynamic Therapy (PDT) and Photodynamic Diagnosis (PDD) in the Department of Surgery, Tokyo Medical University. Photodiagn. Photodyn. Ther. 1, 107–110.

    Not in our library10.1016/s1572-1000(04)00044-4

  147. 147.

    Kausch I. Sommerauer M. Montorsi F. Stenzl A. Jacqmin D. Jichlinski P. (2010 ). Photodynamic Diagnosis in Non-muscle-invasive Bladder Cancer: a Systematic Review and Cumulative Analysis of Prospective Studies. Eur. Urol. 57 (4), 595–606.

    Not in our library10.1016/j.eururo.2009.11.041

  148. 148.

    Kawczyk-Krupka A. Bugaj A. M. Latos W. Zaremba K. Wawrzyniec K. Sieroń A. (2015 ). Photodynamic Therapy in Colorectal Cancer Treatment: the State of the Art in Clinical Trials. Photodiagn. Photodyn. Ther. 12 (3), 545–553.

    Not in our library10.1016/j.pdpdt.2015.04.004

  149. 149.

    Khdair A. Di Chen D. Patil Y. Ma L. Dou Q. P. Shekhar M. P. V. (2010 ). Nanoparticle-mediated Combination Chemotherapy and Photodynamic Therapy Overcomes Tumor Drug Resistance. J. Controlled Release 141 (2), 137–144.

    Not in our library10.1016/j.jconrel.2009.09.004

  150. 150.

    Kim H.-I. Wilson B. C. (2020 ). Photodynamic Diagnosis and Therapy for Peritoneal Carcinomatosis from Gastrointestinal Cancers: Status, Opportunities, and Challenges. J. Gastric Cancer 20 (4), 355–375.

    Not in our library10.5230/jgc.2020.20.e39

  151. 151.

    Kimani S. G. Phillips J. B. Bruce J. I. MacRobert A. J. Golding J. P. (2012 ). Antioxidant Inhibitors Potentiate the Cytotoxicity of Photodynamic Therapy. Photochem. Photobiol. 88 (1), 175–187.

    Not in our library10.1111/j.1751-1097.2011.01022.x

  152. 152.

    Kleinovink J. W. Fransen M. F. Löwik C. W. Ossendorp F. (2017 ). Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8+ T Cells. Cancer Immunol. Res. 5 (10), 832–838.

    Not in our library10.1158/2326-6066.cir-17-0055

  153. 153.

    Korbelik M. Sun J. (2006 ). Photodynamic Therapy-Generated Vaccine for Cancer Therapy. Cancer Immunol. Immunother. 55 (8), 900–909.

    Not in our library10.1007/s00262-005-0088-4

  154. 154.

    Korbelik M. Stott B. Sun J. (2007 ). Photodynamic Therapy-Generated Vaccines: Relevance of Tumour Cell Death Expression. Br. J. Cancer 97 (10), 1381–1387.

    Not in our library10.1038/sj.bjc.6604059

  155. 155.

    Korbelik M. Banáth J. Zhang W. Gallagher P. Hode T. Lam S. S. K. (2019 ). N-dihydrogalactochitosan as Immune and Direct Antitumor Agent Amplifying the Effects of Photodynamic Therapy and Photodynamic Therapy-Generated Vaccines. Int. Immunopharmacology 75, 105764.

    Not in our library10.1016/j.intimp.2019.105764

  156. 156.

    Korbelik M. (2010 ). Photodynamic Therapy-Generated Cancer Vaccines. Methods Mol. Biol. 635, 147–153.

    Not in our library10.1007/978-1-60761-697-9_11

  157. 157.

    Korbelik M. (2019 ). Cancer PDT Vaccines: Progress and Prospects (Conference Presentation). Bellingham, Washington: SPIE.

    Not in our library

  158. 158.
    Porphyrin photosensitizers in photodynamic therapy and its applications · 2017
    No notice
  159. 159.

    Kreso A. Dick J. E. (2014 ). Evolution of the Cancer Stem Cell Model. Cell Stem Cell 14 (3), 275–291.

    Not in our library10.1016/j.stem.2014.02.006

  160. 160.

    Kroemer G. Galluzzi L. Kepp O. Zitvogel L. (2013 ). Immunogenic Cell Death in Cancer Therapy. Annu. Rev. Immunol. 31, 51–72.

    Not in our library10.1146/annurev-immunol-032712-100008

  161. 161.

    Kuijpers D. I. M. Smeets N. W. J. Krekels G. A. M. Thissen M. R. T. M. (2004 ). Photodynamic Therapy as Adjuvant Treatment of Extensive Basal Cell Carcinoma Treated with Mohs Micrographic Surgery. Dermatol. Surg. 30 (5), 794–798.

    Not in our library10.1111/j.1524-4725.2004.30221.x

  162. 162.

    Kuo W.-S. Chang C.-N. Chang Y.-T. Yang M.-H. Chien Y.-H. Chen S.-J. (2010 ). Gold Nanorods in Photodynamic Therapy, as Hyperthermia Agents, and in Near-Infrared Optical Imaging. Angew. Chem. Int. Edition 49 (15), 2711–2715.

    Not in our library10.1002/anie.200906927

  163. 163.

    Kwiatkowski S. Knap B. Przystupski D. Saczko J. Kędzierska E. Knap-Czop K. (2018 ). Photodynamic Therapy - Mechanisms, Photosensitizers and Combinations. Biomed. Pharmacother. 106, 1098–1107.

    Not in our library10.1016/j.biopha.2018.07.049

  164. 164.

    Kwitniewski M. Juzeniene A. Glosnicka R. Moan J. (2008 ). Immunotherapy: a Way to Improve the Therapeutic Outcome of Photodynamic Therapy? Photochem. Photobiol. Sci. 7 (9), 1011–1017.

    Not in our library10.1039/b806710d

  165. 165.
    The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses · 2020
    No notice
  166. 166.

    Lan M. Zhao S. Zhang Z. Yan L. Guo L. Niu G. (2017 ). Two-photon-excited Near-Infrared Emissive Carbon Dots as Multifunctional Agents for Fluorescence Imaging and Photothermal Therapy. Nano Res. 10 (9), 3113–3123.

    Not in our library10.1007/s12274-017-1528-0

  167. 167.

    Lan G. Ni K. Xu Z. Veroneau S. S. Song Y. Lin W. (2018 ). Nanoscale Metal-Organic Framework Overcomes Hypoxia for Photodynamic Therapy Primed Cancer Immunotherapy. J. Am. Chem. Soc. 140 (17), 5670–5673.

    Not in our library10.1021/jacs.8b01072

  168. 168.

    Lee H. M. Jeong Y.-I. Kim D. H. Kwak T. W. Chung C.-W. Kim C. H. (2013 ). Ursodeoxycholic Acid-Conjugated Chitosan for Photodynamic Treatment of HuCC-T1 Human Cholangiocarcinoma Cells. Int. J. Pharmaceutics 454 (1), 74–81.

    Not in our library10.1016/j.ijpharm.2013.06.035

  169. 169.

    Li L.-B. Luo R.-C. (2009 ). Effect of Drug-Light Interval on the Mode of Action of Photofrin Photodynamic Therapy in a Mouse Tumor Model. Lasers Med. Sci. 24 (4), 597–603.

    Not in our library10.1007/s10103-008-0620-9

  170. 170.

    Li L.-b. Luo R.-c. Liao W.-j. Zhang M.-j. Luo Y.-l. Miao J.-x. (2006 ). Clinical Study of Photofrin Photodynamic Therapy for the Treatment of Relapse Nasopharyngeal Carcinoma. Photodiagn. Photodyn. Ther. 3 (4), 266–271.

    Not in our library10.1016/j.pdpdt.2006.09.004

  171. 171.

    Li D. Zhang F. Shi L. Lin L. Cai Q. Xu Y. (2020a ). Treatment of HPV Infection-Associated Low Grade Cervical Intraepithelial Neoplasia with 5-Aminolevulinic Acid-Mediated Photodynamic Therapy. Photodiagn. Photodyn. Ther. 32, 101974.

    Not in our library10.1016/j.pdpdt.2020.101974

  172. 172.

    Li X. Lovell J. F. Yoon J. Chen X. (2020b ). Clinical Development and Potential of Photothermal and Photodynamic Therapies for Cancer. Nat. Rev. Clin. Oncol. 17 (11), 657–674.

    Not in our library10.1038/s41571-020-0410-2

  173. 173.

    Li W.-P. Yen C.-J. Wu B.-S. Wong T.-W. (2021 ). Recent Advances in Photodynamic Therapy for Deep-Seated Tumors with the Aid of Nanomedicine. Biomedicines 9 (1), 69.

    Not in our library10.3390/biomedicines9010069

  174. 174.

    Liang C. Zhang X. Yang M. Wang W. Chen P. Dong X. (2020 ). Remodeling Tumor Microenvironment by Multifunctional Nanoassemblies for Enhanced Photodynamic Cancer Therapy. ACS Mater. Lett. 2 (10), 1268–1286.

    Not in our library10.1021/acsmaterialslett.0c00259

  175. 175.

    Lipson R. L. Baldes E. J. (1960 ). The Photodynamic Properties of a Particular Hematoporphyrin Derivative. Arch. Dermatol. 82, 508–516.

    Not in our library10.1001/archderm.1960.01580040026005

  176. 176.

    Lipson R. L. Baldes E. J. Olsen A. M. (1961 ). Hematoporphyrin Derivative: a New Aid for Endoscopic Detection of Malignant Disease. J. Thorac. Cardiovasc. Surg. 42 (5), 623–629.

    Not in our library10.1016/s0022-5223(19)32560-7

  177. 177.

    Lipson R. L. Baldes E. J. Gray M. J. (1967 ). Hematoporphyrin Derivative for Detection and Management of Cancer. Cancer 20 (12), 2255–2257.

    Not in our library10.1002/1097-0142(196712)20:12<2255::aid-cncr2820201229>3.0.co;2-u

  178. 178.

    Liu Z. Xie Z. Li W. Wu X. Jiang X. Li G. (2021 ). Photodynamic Immunotherapy of Cancers Based on Nanotechnology: Recent Advances and Future Challenges. J. Nanobiotechnol 19 (1), 160.

    Not in our library10.1186/s12951-021-00903-7

  179. 179.

    Los M. Roodhart J. M. L. Voest E. E. (2007 ). Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer. Oncologist 12 (4), 443–450.

    Not in our library10.1634/theoncologist.12-4-443

  180. 180.

    Lotfinejad P. Kazemi T. Mokhtarzadeh A. Shanehbandi D. Jadidi Niaragh F. Safaei S. (2020 ). PD-1/PD-L1 axis Importance and Tumor Microenvironment Immune Cells. Life Sci. 259, 118297.

    Not in our library10.1016/j.lfs.2020.118297

  181. 181.

    Loveday C. Litchfield K. Proszek P. Z. Cornish A. J. Santo F. Levy M. (2020 ). Genomic Landscape of Platinum Resistant and Sensitive Testicular Cancers. Nat. Commun. 11 (1), 2189.

    Not in our library10.1038/s41467-020-15768-x

  182. 182.

    Lu K. He C. Lin W. (2015 ). A Chlorin-Based Nanoscale Metal-Organic Framework for Photodynamic Therapy of Colon Cancers. J. Am. Chem. Soc. 137 (24), 7600–7603.

    Not in our library10.1021/jacs.5b04069

  183. 183.

    Lu K. He C. Guo N. Chan C. Ni K. Weichselbaum R. R. (2016 ). Chlorin-Based Nanoscale Metal-Organic Framework Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy. J. Am. Chem. Soc. 138 (38), 12502–12510.

    Not in our library10.1021/jacs.6b06663

  184. 184.

    Luan S. Tran N. T. Xue H.-Y. Wong H.-L. (2021 ). Development of a High Payload, Cancer-Targeting Liposomes of Methyl Aminolevulinate for Intraoperative Photodynamic Diagnosis/therapy of Peritoneal Carcinomatosis. Int. J. Pharmaceutics 602, 120612.

    Not in our library10.1016/j.ijpharm.2021.120612

  185. 185.

    Luksiene Z. Kalvelyte A. Supino R. (1999 ). On the Combination of Photodynamic Therapy with Ionizing Radiation. J. Photochem. Photobiol. B 52 (1-3), 35–42.

    Not in our library10.1016/s1011-1344(99)00098-6

  186. 186.

    Luo S. Zhang E. Su Y. Cheng T. Shi C. (2011 ). A Review of NIR Dyes in Cancer Targeting and Imaging. Biomaterials 32 (29), 7127–7138.

    Not in our library10.1016/j.biomaterials.2011.06.024

  187. 187.

    Ma L. Iani V. Moan J. (1993 ). Combination Therapy: Photochemotherapy; Electric Current; and Ionizing Radiation. Different Combinations Studied in a WiDr Human colon Adenocarcinoma Cell Line. J. Photochem. Photobiol. B 21 (2-3), 149–154.

    Not in our library10.1016/1011-1344(93)80177-b

  188. 188.

    Ma L. W. Berg K. Danielsen H. E. Kaalhus O. Iani V. Moan J. (1996 ). Enhanced Antitumour Effect of Photodynamic Therapy by Microtubule Inhibitors. Cancer Lett. 109 (1-2), 129–139.

    Not in our library10.1016/s0304-3835(96)04437-0

  189. 189.

    MacCormack M. A. (2006 ). Photodynamic Therapy. Adv. Dermatol. 22, 219–258.

    Not in our library10.1016/j.yadr.2006.09.008

  190. 190.

    Maeding N. Verwanger T. Krammer B. (2016 ). Boosting Tumor-Specific Immunity Using PDT. Cancers 8 (10), 91.

    Not in our library10.3390/cancers8100091

  191. 191.

    Majidinia M. Mirza‐Aghazadeh‐Attari M. Rahimi M. Mihanfar A. Karimian A. Safa A. (2020 ). Overcoming Multidrug Resistance in Cancer: Recent Progress in Nanotechnology and New Horizons. IUBMB Life 72 (5), 855–871.

    Not in our library10.1002/iub.2215

  192. 192.

    McDonagh A. F. (2001 ). Phototherapy: from Ancient Egypt to the New Millennium. J. Perinatol 21 (Suppl. 1), S7–S12.

    Not in our library10.1038/sj.jp.7210625

  193. 193.

    Meng Z. Zhou X. Xu J. Han X. Dong Z. Wang H. (2019 ). Light‐Triggered In Situ Gelation to Enable Robust Photodynamic‐Immunotherapy by Repeated Stimulations. Adv. Mater. 31 (24), 1900927.

    Not in our library10.1002/adma.201900927

  194. 194.

    Merriam-Webster (2021 ). Atharva Veda [Online]. Merriam-Webster.Com Dictionary. Available: https://www.merriam-webster.com/dictionary/Atharva%20Veda. (Accessed Jun 28, 2021).

    Not in our library

  195. 195.

    Mfouo-Tynga I. S. Dias L. D. Inada N. M. Kurachi C. (2021 ). Features of Third Generation Photosensitizers Used in Anticancer Photodynamic Therapy: Review. Photodiagnosis Photodynamic Ther. 34, 102091.

    Not in our library10.1016/j.pdpdt.2020.102091

  196. 196.

    Millington G. W. M. Levell N. J. (2007 ). Vitiligo: the Historical Curse of Depigmentation. Int. J. Dermatol. 46 (9), 990–995.

    Not in our library10.1111/j.1365-4632.2007.03195.x

  197. 197.

    Mitchell M. J. Billingsley M. M. Haley R. M. Wechsler M. E. Peppas N. A. Langer R. (2021 ). Engineering Precision Nanoparticles for Drug Delivery. Nat. Rev. Drug Discov. 20 (2), 101–124.

    Not in our library10.1038/s41573-020-0090-8

  198. 198.

    Mitton D. Ackroyd R. (2008 ). A Brief Overview of Photodynamic Therapy in Europe. Photodiagnosis Photodynamic Ther. 5 (2), 103–111.

    Not in our library10.1016/j.pdpdt.2008.04.004

  199. 199.

    Moan J. Berg K. (1991 ). The Photodegradation of Porphyrins in Cells Can Be Used to Estimate the Lifetime of Singlet Oxygen. Photochem. Photobiol. 53 (4), 549–553.

    Not in our library10.1111/j.1751-1097.1991.tb03669.x

  200. 200.

    Moan J. (1986 ). Porphyrin Photosensitization and Phototherapy. Photochem. Photobiol. 43 (6), 681–690.

    Not in our library10.1111/j.1751-1097.1986.tb05647.x

  201. 201.
    Targeting the indoleamine 2,3-dioxygenase pathway in cancer · 2015
    No notice
  202. 202.

    Moore C. M. Pendse D. Emberton M. (2009 ). Photodynamic Therapy for Prostate Cancer-A Review of Current Status and Future Promise. Nat. Rev. Urol. 6 (1), 18–30.

    Not in our library10.1038/ncpuro1274

  203. 203.

    Moore C. M. Emberton M. Bown S. G. (2011 ). Photodynamic Therapy for Prostate Cancer-An Emerging Approach for Organ-Confined Disease. Lasers Surg. Med. 43 (7), 768–775.

    Not in our library10.1002/lsm.21104

  204. 204.

    Moser J. G. (1998 ). Photodynamic Tumor Therapy: 2nd and 3rd Generation Photosensitizers. Amsterdam: Harwood Academic Publishers.

    Not in our library

  205. 205.

    Mowatt G. N'Dow J. Vale L. Nabi G. Boachie C. Cook J. A. (2011 ). Photodynamic Diagnosis of Bladder Cancer Compared with white Light Cystoscopy: Systematic Review and Meta-Analysis. Int. J. Technol. Assess. Health Care 27 (1), 3–10.

    Not in our library10.1017/s0266462310001364

  206. 206.

    Murata K. Tsukahara T. Torigoe T. (2016 ). Cancer Immunotherapy and Immunological Memory. Jpn. J. Clin. Immunol. 39 (1), 18–22.

    Not in our library10.2177/jsci.39.18

  207. 207.

    Nahabedian M. Y. Cohen R. A. Contino M. F. Terem T. M. Wright W. H. Berns M. W. (1988 ). Combination Cytotoxic Chemotherapy With Cisplatin or Doxorubicin and Photodynamic Therapy in Murine Tumors1. JNCI J. Natl. Cancer Inst. 80 (10), 739–743.

    Not in our library10.1093/jnci/80.10.739

  208. 208.

    Nakano A. Watanabe D. Akita Y. Kawamura T. Tamada Y. Matsumoto Y. (2011 ). Treatment Efficiency of Combining Photodynamic Therapy and Ionizing Radiation for Bowen's Disease. J. Eur. Acad. Dermatol. Venereol. 25 (4), 475–478.

    Not in our library10.1111/j.1468-3083.2010.03757.x

  209. 209.

    Nanashima A. Yamaguchi H. Shibasaki S. Ide N. Sawai T. Tsuji T. (2004 ). Adjuvant Photodynamic Therapy for Bile Duct Carcinoma after Surgery: a Preliminary Study. J. Gastroenterol. 39 (11), 1095–1101.

    Not in our library10.1007/s00535-004-1449-z

  210. 210.

    Narumi A. Tsuji T. Shinohara K. Yamazaki H. Kikuchi M. Kawaguchi S. (2016 ). Maltotriose-conjugation to a Fluorinated Chlorin Derivative Generating a PDT Photosensitizer with Improved Water-Solubility. Org. Biomol. Chem. 14 (14), 3608–3613.

    Not in our library10.1039/c6ob00276e

  211. 211.

    Naylor M. F. Chen W. R. Teague T. K. Perry L. A. Nordquist R. E. (2006 ). In Situ photoimmunotherapy: a Tumour-Directed Treatment for Melanoma. Br. J. Dermatol. 155 (6), 1287–1292.

    Not in our library10.1111/j.1365-2133.2006.07514.x

  212. 212.

    Ng C. W. Li J. Pu K. (2018 ). Recent Progresses in Phototherapy-Synergized Cancer Immunotherapy. Adv. Funct. Mater. 28 (46), 1804688.

    Not in our library10.1002/adfm.201804688

  213. 213.

    Niculescu A.-G. Grumezescu A. M. (2021 ). Photodynamic Therapy-An Up-To-Date Review. Appl. Sci. 11 (8), 3626.

    Not in our library10.3390/app11083626

  214. 214.

    Nishie H. Kataoka H. Yano S. Kikuchi J.-i. Hayashi N. Narumi A. (2016 ). A Next-Generation Bifunctional Photosensitizer with Improved Water-Solubility for Photodynamic Therapy and Diagnosis. Oncotarget 7 (45), 74259–74268.

    Not in our library10.18632/oncotarget.12366

  215. 215.

    Nishiyama N. Morimoto Y. Jang W.-D. Kataoka K. (2009 ). Design and Development of Dendrimer Photosensitizer-Incorporated Polymeric Micelles for Enhanced Photodynamic Therapy. Adv. Drug Deliv. Rev. 61 (4), 327–338.

    Not in our library10.1016/j.addr.2009.01.004

  216. 216.

    NobelPrize.orgThe Nobel Prize in Physiology or Medicine 1903. [Online]. Nobel Media AB 2021. Available: https://www.nobelprize.org/prizes/medicine/1903/summary/. (Accessed Mon.June 28, 2021).

    Not in our library

  217. 217.

    Nokes B. Apel M. Jones C. Brown G. Lang J. E. (2013 ). Aminolevulinic Acid (ALA): Photodynamic Detection and Potential Therapeutic Applications. J. Surg. Res. 181 (2), 262–271.

    Not in our library10.1016/j.jss.2013.02.002

  218. 218.

    Nompumelelo Simelane N. W. Kruger C. A. Abrahamse H. (2020 ). Photodynamic Diagnosis and Photodynamic Therapy of Colorectal Cancer In Vitro and In Vivo. RSC Adv. 10 (68), 41560–41576.

    Not in our library10.1039/d0ra08617g

  219. 219.

    Nowis D. Makowski M. Stokłosa T. Legat M. Issat T. Gołab J. (2005 ). Direct Tumor Damage Mechanisms of Photodynamic Therapy. Acta Biochim. Pol. 52 (2), 339–352.

    Not in our library10.18388/abp.2005_3447

  220. 220.

    NXDC (2018 ). Gleolan (Aminolevulinic Acid Hydrochloride) [package Insert]. U.S. Food and Drug Administration Website. Revised August 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208630s003lbl.pdf. (Accessed Mar 14, 2021).

    Not in our library

  221. 221.

    O’Connor A. E. Gallagher W. M. Byrne A. T. (2009 ). Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. Photochem. Photobiol. 85 (5), 1053–1074.

    Not in our library10.1111/j.1751-1097.2009.00585.x

  222. 222.

    Owari T. Iwamoto T. Anai S. Miyake M. Nakai Y. Hori S. (2021 ). The Sustaining of Fluorescence in Photodynamic Diagnosis after the Administration of 5-aminolevulinic Acid in Carcinogen-Induced Bladder Cancer Orthotopic Rat Model and Urothelial Cancer Cell Lines. Photodiagn. Photodyn. Ther. 34, 102309.

    Not in our library10.1016/j.pdpdt.2021.102309

  223. 223.

    Oyim J. Omolo C. A. Amuhaya E. K. (2021 ). Photodynamic Antimicrobial Chemotherapy: Advancements in Porphyrin-Based Photosensitize Development. Front. Chem. 9, 635344.

    Not in our library10.3389/fchem.2021.635344

  224. 224.

    Park J.-J. Thi E. P. Carpio V. H. Bi Y. Cole A. G. Dorsey B. D. (2021 ). Checkpoint Inhibition through Small Molecule-Induced Internalization of Programmed Death-Ligand 1. Nat. Commun. 12 (1), 1222.

    Not in our library10.1038/s41467-021-21410-1

  225. 225.

    Pass H. I. (1993 ). Photodynamic Therapy in Oncology: Mechanisms and Clinical Use. JNCI J. Natl. Cancer Inst. 85 (6), 443–456.

    Not in our library10.1093/jnci/85.6.443

  226. 226.

    Pedone D. Moglianetti M. De Luca E. Bardi G. Pompa P. P. (2017 ). Platinum Nanoparticles in Nanobiomedicine. Chem. Soc. Rev. 46 (16), 4951–4975.

    Not in our library10.1039/c7cs00152e

  227. 227.

    Pernot M. Frochot C. Vanderesse R. Barberi-Heyob M. (2013 ). “Targeting Strategies in Photodynamic Therapy for Cancer Treatment,” in Handbook of Photomedicine. Editors Hamblin M. R. Huang Y. 1st Edition ed (Boca Raton: CRC Press).

    Not in our library10.1201/b15582-35

  228. 228.

    Persidis A. (1999 ). Cancer Multidrug Resistance. Nat. Biotechnol. 17 (1), 94–95.

    Not in our library10.1038/5289

  229. 229.

    Peterson C. M. Reed R. Jolles C. J. Jones K. P. Straight R. C. Poulson A. M. (1992 ). Photodynamic Therapy of Human Ovarian Epithelial Carcinoma, OVCAR-3, Heterotransplanted in the Nude Mouse. Am. J. Obstet. Gynecol. 167 (6), 1852–1855.

    Not in our library10.1016/0002-9378(92)91786-a

  230. 230.

    Peterson C. M. Lu J. M. Sun Y. Peterson C. A. Shiah J. G. Straight R. C. (1996 ). Combination Chemotherapy and Photodynamic Therapy with N-(2-hydroxypropyl) Methacrylamide Copolymer-Bound Anticancer Drugs Inhibit Human Ovarian Carcinoma Heterotransplanted in Nude Mice. Cancer Res. 56 (17), 3980–3985.

    Not in our library

  231. 231.

    Photocure ASA (2018 ). Cysview (Hexaminolevulinate Hydrochloride) [package Insert]. U.S. Food and Drug Administration Website. Revised Februrary 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022555s005lbl.pdf. (Accessed Mar 14, 2021).

    Not in our library

  232. 232.

    Pinnacle Biolgs (2020 ). Photofrin (Porfimer Sodium) [package Insert]. U.S. Food and Drug Administration Website. Revised January 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020451s029,021525s005lbl.pdf. (Accessed Mar 14, 2021).

    Not in our library

  233. 233.

    Qiu H. Kim M. M. Penjweini R. Finlay J. C. Busch T. M. Wang T. (2017 ). A Comparison of Dose Metrics to Predict Local Tumor Control for Photofrin-Mediated Photodynamic Therapy. Photochem. Photobiol. 93 (4), 1115–1122.

    Not in our library10.1111/php.12719

  234. 234.

    Quintana E. Shackleton M. Sabel M. S. Fullen D. R. Johnson T. M. Morrison S. J. (2008 ). Efficient Tumour Formation by Single Human Melanoma Cells. Nature 456 (7222), 593–598.

    Not in our library10.1038/nature07567

  235. 235.

    Quirk B. J. Brandal G. Donlon S. Vera J. C. Mang T. S. Foy A. B. (2015 ). Photodynamic Therapy (PDT) for Malignant Brain Tumors - Where Do We Stand? Photodiagn. Photodyn. Ther. 12 (3), 530–544.

    Not in our library10.1016/j.pdpdt.2015.04.009

  236. 236.

    Raab O. (1900 ). Uber die wirkung Fluorescirender Stoffe auf Infusorien. Z. Biol. 39, 524–546.

    Not in our library

  237. 237.

    Railkar R. Agarwal P. K. (2018 ). Photodynamic Therapy in the Treatment of Bladder Cancer: Past Challenges and Current Innovations. Eur. Urol. Focus 4 (4), 509–511.

    Not in our library10.1016/j.euf.2018.08.005

  238. 238.

    Rapacka-Zdończyk A. Woźniak A. Michalska K. Pierański M. Ogonowska P. Grinholc M. (2021 ). Factors Determining the Susceptibility of Bacteria to Antibacterial Photodynamic Inactivation. Front. Med. 8, 642609.

    Not in our library10.3389/fmed.2021.642609

  239. 239.

    Rasmussen-Taxdal D. S. Ward G. E. Figge F. H. (1955 ). Fluorescence of Human Lymphatic and Cancer Tissues Following High Doses of Intravenous Hematoporphyrin. Surg. Forum 5, 619–624.

    Not in our library

  240. 240.

    Reginato E. Wolf P. Hamblin M. R. (2014 ). Immune Response after Photodynamic Therapy Increases Anti-cancer and Anti-bacterial Effects. Wji 4 (1), 1–11.

    Not in our library10.5411/wji.v4.i1.1

  241. 241.

    Rigual N. R. Shafirstein G. Frustino J. Seshadri M. Cooper M. Wilding G. (2013 ). Adjuvant Intraoperative Photodynamic Therapy in Head and Neck Cancer. JAMA Otolaryngol. Head Neck Surg. 139 (7), 706–711.

    Not in our library10.1001/jamaoto.2013.3387

  242. 242.

    Ris H.-B. (2005 ). Photodynamic Therapy as an Adjunct to Surgery for Malignant Pleural Mesothelioma. Lung Cancer 49 (Suppl. 1), S65–S68.

    Not in our library10.1016/j.lungcan.2005.03.024

  243. 243.
    A decade of immune-checkpoint inhibitors in cancer therapy · 2020
    No notice
  244. 244.

    Roelandts R. (1991 ). The History of Photochemotherapy. Photodermatol. Photoimmunol Photomed. 8 (5), 184–189.

    Not in our library

  245. 245.

    Rossi M. Carioli G. Bonifazi M. Zambelli A. Franchi M. Moja L. (2016 ). Trastuzumab for HER2+ Metastatic Breast Cancer in Clinical Practice: Cardiotoxicity and Overall Survival. Eur. J. Cancer 52, 41–49.

    Not in our library10.1016/j.ejca.2015.09.012

  246. 246.
    Photosensitizer in lipid nanoparticle: a nano-scaled approach to antibacterial function · 2017
    Not checked
  247. 247.

    Saji H. Song W. Furumoto K. Kato H. Engleman E. G. (2006 ). Systemic Antitumor Effect of Intratumoral Injection of Dendritic Cells in Combination with Local Photodynamic Therapy. Clin. Cancer Res. 12 (8), 2568–2574.

    Not in our library10.1158/1078-0432.ccr-05-1986

  248. 248.

    Santos L. L. Oliveira J. Monteiro E. Santos J. Sarmento C. (2018 ). Treatment of Head and Neck Cancer with Photodynamic Therapy with Redaporfin: A Clinical Case Report. Case Rep. Oncol. 11 (3), 769–776.

    Not in our library10.1159/000493423

  249. 249.

    Savellano M. D. Pogue B. W. Hoopes P. J. Vitetta E. S. Paulsen K. D. (2005 ). Multiepitope HER2 Targeting Enhances Photoimmunotherapy of HER2-Overexpressing Cancer Cells with Pyropheophorbide-A Immunoconjugates. Cancer Res. 65 (14), 6371–6379.

    Not in our library10.1158/0008-5472.can-05-0426

  250. 250.

    Schmidt-Erfurth U. Miller J. Sickenberg M. Bunse A. Laqua H. Gragoudas E. (1998 ). Photodynamic Therapy of Subfoveal Choroidal Neovascularization: Clinical and Angiographic Examples. Graefe's Archive Clin. Exp. Ophthalmol. 236 (5), 365–374.

    Not in our library10.1007/s004170050092

  251. 251.

    Schmitt F. Juillerat-Jeanneret L. (2012 ). Drug Targeting Strategies for Photodynamic Therapy. Acamc 12 (5), 500–525.

    Not in our library10.2174/187152012800617830

  252. 252.

    Senge M. O. (2012 ). mTHPC - A Drug on its Way from Second to Third Generation Photosensitizer? Photodiagn. Photodyn. Ther. 9 (2), 170–179.

    Not in our library10.1016/j.pdpdt.2011.10.001

  253. 253.

    Shen Z. Ma Q. Zhou X. Zhang G. Hao G. Sun Y. (2021 ). Strategies to Improve Photodynamic Therapy Efficacy by Relieving the Tumor Hypoxia Environment. NPG Asia Mater. 13 (1), 39.

    Not in our library10.1038/s41427-021-00303-1

  254. 254.

    Shi J. Su Y. Liu W. Chang J. Zhang Z. (2017 ). A Nanoliposome-Based Photoactivable Drug Delivery System for Enhanced Cancer Therapy and Overcoming Treatment Resistance. Ijn Vol. 12, 8257–8275.

    Not in our library10.2147/ijn.s143776

  255. 255.

    Shirasu N. Nam S. O. Kuroki M. (2013 ). Tumor-targeted Photodynamic Therapy. Anticancer Res. 33 (7), 2823–2831.

    Not in our library

  256. 256.

    Shu M. Yan H. Xu C. Wu Y. Chi Z. Nian W. (2020 ). A Novel Anti-HER2 Antibody GB235 Reverses Trastuzumab Resistance in HER2-Expressing Tumor Cells In Vitro and In Vivo. Sci. Rep. 10 (1), 2986.

    Not in our library10.1038/s41598-020-59818-2

  257. 257.

    Siegel R. L. Miller K. D. Jemal A. (2020 ). Cancer Statistics, 2020. CA A. Cancer J. Clin. 70 (1), 7–30.

    Not in our library10.3322/caac.21590

  258. 258.

    Sirotkina M. A. Moiseev A. A. Matveev L. A. Zaitsev V. Y. Elagin V. V. Kuznetsov S. S. (2019 ). Accurate Early Prediction of Tumour Response to PDT Using Optical Coherence Angiography. Sci. Rep. 9 (1), 6492.

    Not in our library10.1038/s41598-019-43084-y

  259. 259.

    Song W. Kuang J. Li C.-X. Zhang M. Zheng D. Zeng X. (2018 ). Enhanced Immunotherapy Based on Photodynamic Therapy for Both Primary and Lung Metastasis Tumor Eradication. ACS Nano. 12 (2), 1978–1989.

    Not in our library10.1021/acsnano.7b09112

  260. 260.

    Sorrin A. J. Kemal Ruhi M. Ferlic N. A. Karimnia V. Polacheck W. J. Celli J. P. (2020 ). Photodynamic Therapy and the Biophysics of the Tumor Microenvironment. Photochem. Photobiol. 96 (2), 232–259.

    Not in our library10.1111/php.13209

  261. 261.

    Spikes J. D. (1990 ). New Trends in Photobiology. J. Photochem. Photobiol. B: Biol. 6 (3), 259–274.

    Not in our library10.1016/1011-1344(90)85096-f

  262. 262.

    Staneloudi C. Smith K. A. Hudson R. Malatesti N. Savoie H. Boyle R. W. (2007 ). Development and Characterization of Novel Photosensitizer: scFv Conjugates for Use in Photodynamic Therapy of Cancer. Immunology 120 (4), 512–517.

    Not in our library10.1111/j.1365-2567.2006.02522.x

  263. 263.

    Stenson K. M. (2021 ). in Epidemiology and Risk Factors for Head and Neck Cancer. Editor Post T.W. (Waltham, MA: UpToDate)).

    Not in our library

  264. 264.

    Stolik S. Delgado J. A. Pérez A. Anasagasti L. (2000 ). Measurement of the Penetration Depths of Red and Near Infrared Light in Human "Ex Vivo" Tissues. J. Photochem. Photobiol. B 57 (2-3), 90–93.

    Not in our library10.1016/s1011-1344(00)00082-8

  265. 265.

    Stummer W. Pichlmeier U. Meinel T. Wiestler O. D. Zanella F. Reulen H.-J. (2006 ). Fluorescence-guided Surgery with 5-aminolevulinic Acid for Resection of Malignant Glioma: a Randomised Controlled Multicentre Phase III Trial. Lancet Oncol. 7 (5), 392–401.

    Not in our library10.1016/s1470-2045(06)70665-9

  266. 266.

    Sun B. Li W. Liu N. (2016 ). Curative Effect of the Recent Photofrin Photodynamic Adjuvant Treatment on Young Patients with Advanced Colorectal Cancer. Oncol. Lett. 11 (3), 2071–2074.

    Not in our library10.3892/ol.2016.4179

  267. 267.

    Sung H. Ferlay J. Siegel R. L. Laversanne M. Soerjomataram I. Jemal A. (2021 ). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A. Cancer J. Clin. 71 (3), 209–249.

    Not in our library10.3322/caac.21660

  268. 268.

    Tappeiner H. (1909 ). Die photodynamische Erscheinung (Sensibilisierung durch fluoreszierende Stoffe). Ergebnisse der Physiologie 8 (1), 698–741.

    Not in our library10.1007/bf0232109610.1007/bf01951514

  269. 269.

    Torres T. Fernandes I. Costa V. Selores M. (2011 ). Photodynamic Therapy as Adjunctive Therapy for Morpheaform Basal Cell Carcinoma. Acta Dermatovenerol Alp Pannonica Adriat 20 (1), 23–25.

    Not in our library

  270. 270.

    Trempolec N. Doix B. Degavre C. Brusa D. Bouzin C. Riant O. (2020 ). Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma. Cancers 12 (3), 545.

    Not in our library10.3390/cancers12030545

  271. 271.

    Triesscheijn M. Baas P. Schellens J. H. M. Stewart F. A. (2006 ). Photodynamic Therapy in Oncology. Oncologist 11 (9), 1034–1044.

    Not in our library10.1634/theoncologist.11-9-1034

  272. 272.

    Turan I. S. Yildiz D. Turksoy A. Gunaydin G. Akkaya E. U. (2016 ). A Bifunctional Photosensitizer for Enhanced Fractional Photodynamic Therapy: Singlet Oxygen Generation in the Presence and Absence of Light. Angew. Chem. Int. Ed. 55 (8), 2875–2878.

    Not in our library10.1002/anie.201511345

  273. 273.

    Turan I. S. Gunaydin G. Ayan S. Akkaya E. U. (2018 ). Molecular Demultiplexer as a Terminator Automaton. Nat. Commun. 9 (1), 805.

    Not in our library10.1038/s41467-018-03259-z

  274. 274.

    Urbach F. Forbes P. D. Davies R. E. Berger D. (1976 ). Cutaneous Photobiology: Past, Present and Future. J. Invest. Dermatol. 67 (1), 209–224.

    Not in our library10.1111/1523-1747.ep12513042

  275. 275.

    Usuda J. Kato H. Okunaka T. Furukawa K. Tsutsui H. Yamada K. (2006 ). Photodynamic Therapy (PDT) for Lung Cancers. J. Thorac. Oncol. 1 (5), 489–493.

    Not in our library10.1016/s1556-0864(15)31616-6

  276. 276.

    van Doeveren T. E. M. Karakullukçu M. B. van Veen R. L. P. Lopez-Yurda M. Schreuder W. H. Tan I. B. (2018 ). Adjuvant Photodynamic Therapy in Head and Neck Cancer after Tumor-Positive Resection Margins. Laryngoscope 128 (3), 657–663.

    Not in our library10.1002/lary.26792

  277. 277.
    Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions · 2017
    No notice
  278. 278.

    Vander Heiden M. G. Cantley L. C. Thompson C. B. (2009 ). Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science 324 (5930), 1029–1033.

    Not in our library10.1126/science.1160809

  279. 279.

    Verger A. Brandhonneur N. Molard Y. Cordier S. Kowouvi K. Amela-Cortes M. (2021 ). From Molecules to Nanovectors: Current State of the Art and Applications of Photosensitizers in Photodynamic Therapy. Int. J. Pharmaceutics 604, 120763.

    Not in our library10.1016/j.ijpharm.2021.120763

  280. 280.

    Wang Z. Ma R. Yan L. Chen X. Zhu G. (2015 ). Combined Chemotherapy and Photodynamic Therapy Using a Nanohybrid Based on Layered Double Hydroxides to Conquer Cisplatin Resistance. Chem. Commun. 51 (58), 11587–11590.

    Not in our library10.1039/c5cc04376j

  281. 281.

    Wang D. Wang T. Liu J. Yu H. Jiao S. Feng B. (2016 ). Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy. Nano Lett. 16 (9), 5503–5513.

    Not in our library10.1021/acs.nanolett.6b01994

  282. 282.

    Wang X. Ramamurthy G. Shirke A. A. Walker E. Mangadlao J. Wang Z. (2020a ). Photodynamic Therapy Is an Effective Adjuvant Therapy for Image-Guided Surgery in Prostate Cancer. Cancer Res. 80 (2), 156–162.

    Not in our library10.1158/0008-5472.can-19-0201

  283. 283.

    Wang Y. Wang H. Zhou L. Lu J. Jiang B. Liu C. (2020b ). Photodynamic Therapy of Pancreatic Cancer: Where Have We Come from and where Are We Going? Photodiagn. Photodyn. Ther. 31, 101876.

    Not in our library10.1016/j.pdpdt.2020.101876

  284. 284.

    Wang K. Yu B. Pathak J. L. (2021 ). An Update in Clinical Utilization of Photodynamic Therapy for Lung Cancer. J. Cancer 12 (4), 1154–1160.

    Not in our library10.7150/jca.51537

  285. 285.

    Warrier A. Mazumder N. Prabhu S. Satyamoorthy K. Murali T. S. (2021 ). Photodynamic Therapy to Control Microbial Biofilms. Photodiagnosis Photodynamic Ther. 33, 102090.

    Not in our library10.1016/j.pdpdt.2020.102090

  286. 286.

    Wieder M. E. Hone D. C. Cook M. J. Handsley M. M. Gavrilovic J. Russell D. A. (2006 ). Intracellular Photodynamic Therapy with Photosensitizer-Nanoparticle Conjugates: Cancer Therapy Using a 'Trojan Horse'. Photochem. Photobiol. Sci. 5 (8), 727–734.

    Not in our library10.1039/b602830f

  287. 287.

    Wilson B. C. Patterson M. S. (2008 ). The Physics, Biophysics and Technology of Photodynamic Therapy. Phys. Med. Biol. 53 (9), R61–R109.

    Not in our library10.1088/0031-9155/53/9/r01

  288. 288.

    Wöhrle D. Hirth A. Bogdahn-Rai T. Schnurpfeil G. Shopova M. (1998 ). Photodynamic Therapy of Cancer: Second and Third Generations of Photosensitizers. Russ. Chem. Bull. 47 (5), 807–816.

    Not in our library10.1007/bf02498146

  289. 289.

    Xu J. Xu L. Wang C. Yang R. Zhuang Q. Han X. (2017 ). Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer. ACS Nano 11 (5), 4463–4474.

    Not in our library10.1021/acsnano.7b00715

  290. 290.

    Xu J. Saklatvala R. Mittal S. Deshmukh S. Procopio A. (2020 ). Recent Progress of Potentiating Immune Checkpoint Blockade with External Stimuli-An Industry Perspective. Adv. Sci. 7 (8), 1903394.

    Not in our library10.1002/advs.201903394

  291. 291.

    Yang L. Zhang S. Ling X. Shao P. Jia N. Bai M. (2017 ). Multilayer Photodynamic Therapy for Highly Effective and Safe Cancer Treatment. Acta Biomater. 54, 271–280.

    Not in our library10.1016/j.actbio.2017.03.012

  292. 292.

    Yang H. Liu R. Xu Y. Qian L. Dai Z. (2021 ). Photosensitizer Nanoparticles Boost Photodynamic Therapy for Pancreatic Cancer Treatment. Nano-micro Lett. 13 (1), 35.

    Not in our library10.1007/s40820-020-00561-8

  293. 293.

    Yanovsky R. L. Bartenstein D. W. Rogers G. S. Isakoff S. J. Chen S. T. (2019 ). Photodynamic Therapy for Solid Tumors: A Review of the Literature. Photodermatol. Photoimmunol Photomed. 35 (5), 295–303.

    Not in our library10.1111/phpp.12489

  294. 294.

    Yin T. Wang Z. Li X. Li Y. Bian K. Cao W. (2017 ). Biologically Inspired Self-Assembly of Bacitracin-Based Platinum Nanoparticles with Anti-tumor Effects. New J. Chem. 41 (8), 2941–2948.

    Not in our library10.1039/c6nj03302d

  295. 295.

    Yoo J.-O. Ha K.-S. (2012 ). New Insights into the Mechanisms for Photodynamic Therapy-Induced Cancer Cell Death. Int. Rev. Cel Mol Biol. 295, 139–174.

    Not in our library10.1016/b978-0-12-394306-4.00010-1

  296. 296.

    Yu X. Ghamande S. Liu H. Xue L. Zhao S. Tan W. (2018 ). Targeting EGFR/HER2/HER3 with a Three-In-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer. Mol. Ther. - Nucleic Acids 10, 317–330.

    Not in our library10.1016/j.omtn.2017.12.015

  297. 297.

    Zeitouni N. C. Shieh S. Oseroff A. R. (2001 ). Laser and Photodynamic Therapy in the Management of Cutaneous Malignancies. Clin. Dermatol. 19 (3), 328–338.

    Not in our library10.1016/s0738-081x(01)00170-5

  298. 298.

    Zhang Q. Cai Y. Li Q.-Y. Hao L.-N. Ma Z. Wang X.-J. (2017 ). Targeted Delivery of a Mannose-Conjugated BODIPY Photosensitizer by Nanomicelles for Photodynamic Breast Cancer Therapy. Chem. Eur. J. 23 (57), 14307–14315.

    Not in our library10.1002/chem.201702935

  299. 299.

    Zhang H. Wang P. Wang X. Shi L. Fan Z. Zhang G. (2018a ). Antitumor Effects of DC Vaccine With ALA-PDT-Induced Immunogenic Apoptotic Cells for Skin Squamous Cell Carcinoma in Mice. Technol. Cancer Res. Treat. 17, 153303381878527.

    Not in our library10.1177/1533033818785275

  300. 300.

    Zhang J. Zhang S. Liu Y. Su M. Ling X. Liu F. (2018b ). Combined CB2 Receptor Agonist and Photodynamic Therapy Synergistically Inhibit Tumor Growth in Triple Negative Breast Cancer. Photodiagn. Photodyn. Ther. 24, 185–191.

    Not in our library10.1016/j.pdpdt.2018.09.006

  301. 301.

    Zhang Q. Wu L. Liu S. Chen Q. Zeng L. Chen X. (2020 ). Targeted Nanobody Complex Enhanced Photodynamic Therapy for Lung Cancer by Overcoming Tumor Microenvironment. Cancer Cel Int 20 (1), 570.

    Not in our library10.1186/s12935-020-01613-0

  302. 302.

    Zhang Z. Li A. Min X. Zhang Q. Yang J. Chen G. (2021 ). An ROS-Sensitive Tegafur-PpIX-Heterodimer-Loaded In Situ Injectable Thermosensitive Hydrogel for Photodynamic Therapy Combined with Chemotherapy to Enhance the Tegafur-Based Treatment of Breast Cancer. Biomater. Sci. 9 (1), 221–237.

    Not in our library10.1039/d0bm01519a

  303. 303.
    Nanotechnology for Cancer Therapy Based on Chemotherapy · 2018
    No notice
  304. 304.

    Zhao X. Liu J. Fan J. Chao H. Peng X. (2021 ). Recent Progress in Photosensitizers for Overcoming the Challenges of Photodynamic Therapy: from Molecular Design to Application. Chem. Soc. Rev. 50 (6), 4185–4219.

    Not in our library10.1039/d0cs00173b

  305. 305.

    Zhou Q. Olivo M. Lye K. Y. K. Moore S. Sharma A. Chowbay B. (2005 ). Enhancing the Therapeutic Responsiveness of Photodynamic Therapy with the Antiangiogenic Agents SU5416 and SU6668 in Murine Nasopharyngeal Carcinoma Models. Cancer Chemother. Pharmacol. 56 (6), 569–577.

    Not in our library10.1007/s00280-005-1017-0

Cited by papers we hold 6

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.